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ABSTRACT
Endotoxin recognition by the innate immune receptor CD14 is a critical
part of the innate immune system’s early detection and activation of the inflammatory
response during microbial invasion. The differential recognition and high affinity binding
of endotoxins from gram-negative and gram-positive bacteria is performed by the innate
immune receptor CD14. Upon endotoxin binding, CD14 transfers the specific endotoxins
to a Toll-like receptor signaling complex, which is responsible for initiating the
intracellular signaling cascade. In the presence of overwhelming infection, the effects of
CD14 lead to the over-activation of the inflammatory response, which results in the life
threatening condition known as sepsis.
Preparation of a 15N isotopically labeled truncated version of soluble CD14, using
Pichia pastoris, allowed direct structural observation of the binding interaction between
CD14 and two endotoxin ligands, lipopolysaccharide (LPS) and lipoteichoic acid (LTA),
from gram-negative and gram-positive bacteria, respectively using solution NMR
spectroscopy. These studies revealed that CD14 uses both a common set of residues, and
endotoxin specific subsets of residues, to bind LPS and LTA.
To further investigate the structural features of each endotoxin recognized by
CD14,
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N isotopically labeled Kdo 2 –Lipid A, a fully active chemically defined

gram-negative endotoxin, and LTA lipid anchor, the minimal unit of LTA, were
produced. This allowed detailed NMR spectral mapping of these agonist ligands bound to
sCD14 which identified, for the first time, structural regions and features in each that are
strongly affected during complex formation with sCD14.
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Additionally, the presence of differential dynamic behavior was seen in both
CD14 and the ligands upon complexation. This behavior suggests a likely role for
dynamics in the mechanism of pattern recognition by CD14, which uses the dynamic
ability of specific residue combinations to differentially affect endotoxin binding. Using
NMR, the dynamic behavior of CD14 was further investigated using temperature and pHdependence studies of isotopically labeled CD14. These studies clearly demonstrated the
presence of multiple conformations for several residues, and may provide a possible
explanation for the broad specificity of ligand binding by CD14.
In addition, the spin-labeling of isotopically labeled lipid A enabled the collection
of intermolecular distances on CD14 bound lipid A.
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CHAPTER 1. BACKGROUND AND INTRODUCTION
1.1 THE IMPACT OF SEPSIS
Sepsis is a condition resulting from overwhelming infection; the host’s innate
inflammatory response becomes over-activated causing dire physiological effects known
collectively as sepsis or septic shock. The over-activation of the inflammatory response
in sepsis can ultimately lead to multiple organ failure and death. Sepsis is one of the
leading causes of death worldwide. During host infection, a wide variety of bacterial and
microbial endotoxins such as lipopolysaccharide (LPS) and lipoteichoic acid (LTA) are
responsible for activating the non-specific inflammatory response. In the past, gramnegative bacterial infections were the primary cause of sepsis, but since the late 1980’s
gram-positive bacteria have also become a leading cause of sepsis in the United States
(1).
Sepsis is a growing global health threat requiring an increasing allocation of
resources. Advances in medical treatments and technologies have lengthened the time
that patients can survive with serious underlying medical issues, which compromise their
immune systems, and often necessitate extended hospitalizations or immunosuppressive
therapies. There are approximately 750,000 cases of sepsis in the US each year resulting
in roughly 215,000 fatalities (2). The overall mortality rate for sepsis is 30%. In the
elderly, the rate rises to 40% and in severe cases of sepsis, known as septic shock, the
mortality rate exceeds 50% (3). As the US population continues to shift
disproportionately towards an elderly populace the occurrence of severe sepsis is
1

projected to exceed the rate of population growth within 50 years (2).

The rising

incidence of sepsis is further compounded by the escalating occurrence of antibiotic
resistant bacterial strains and their growing prevalence as a source of nosocomial
infections (4).
In 2003 the Society of Critical Care Medicine, the European Society of Intensive
Care Medicine, and the International Sepsis Forum launched the Surviving Sepsis
Campaign with the objective of reducing severe sepsis mortalities by 25% over five
years. While successful in improving patient outcomes and early sepsis identification and
treatment, the campaign, which concluded in 2008, was only able to reduce the ICU
mortality rate for participating hospitals by 20% (5). A major limitation in combating
sepsis still remains the lack of effective treatments for sepsis in addition to treatment of
the ensuing dysregulation it causes. At this time, drotrecogin alfa (activated), the only
drug FDA approved to combat the effects of septic shock yields only a 6.1% reduction in
absolute risk of death, and increases the risk of serious bleeding events (6).
Understanding how the innate immune receptor CD14 recognizes endotoxins and
facilitates the over-activation of the inflammatory response may hold the key to
advancing the fight against sepsis.

1.2 SEPSIS AND THE INFLAMMATORY RESPONSE
There are three stages of sepsis, progressively increasing in both severity and
mortality rate. The characterization of each stage was defined by the international sepsis
definition conference with the first stage being sepsis, which is defined “by the presence
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of both infection and a systemic inflammatory response”. The second stage is severe
sepsis, which is characterized as “sepsis complicated by organ dysfunction”, and the most
advanced stage is known as septic shock, which is “a state of acute circulatory failure
characterized by persistent arterial hypotension unexplained by another cause” (7).
Because these definitions do not describe individual disorders, but rather the differences
between the escalating stages of severity in the same condition, for simplicity sake, the
term sepsis will be used to refer to all three stages in this dissertation.
The inflammatory response is the non-specific, rapid response to general injury or
infection in a host. This non-specific response allows a host to mount an immediate
defense to an infection or injury much earlier than the pathogen specific adaptive immune
response that follows. Inflammation also plays a critical role in many other biological
processes from chronic inflammatory diseases such as rheumatoid arthritis,
atherosclerosis, chronic pulmonary disease, and even contributes to increased insulin
resistance in diabetics (8-11). In the case of infection, the innate immune system typically
responds to a component of a bacterial invader’s cell wall known as an endotoxin. In the
case of a gram-negative bacterial infection, the endotoxin is the cell wall component LPS.
In essence, the LPS molecule is first bound by the lipopolysaccharide-binding protein
(LBP), followed by transfer of the LPS molecule to CD14, the primary innate immune
receptor. CD14 is principally located on the surface of macrophages and monocytes (12).
The CD14-bound LPS is then presented to the Toll-like receptor 4 transmembrane
signaling complex resulting in the initiation of an inflammatory response (Figure 1.1).
Activation of the inflammatory response leads to initiation of a signaling cascade,
3

described in greater detail later, which results in a massive mobilization of proinflammatory mediators, such as cytokines, chemokines, prostaglandins, lipid mediators,
and reactive oxygen species (3, 13). In addition, this innate immune response triggers the
activation and movement of several types of immune cells, including leukocytes,
neutrophils, and macrophages, from the capillaries into the surrounding tissues (13). The
recruitment of activated immune cells to a site of need introduces additional quantities of
pro-inflammatory mediators stimulating the coagulation cascade. The influx of cytokines
in combination with increased blood flow and activation of the coagulation cascade leads
to a general “leakiness” of the tissues at and around the site(s) of inflammation (13-15).
This vascular and endothelial compromise becomes increasingly severe as sepsis
progresses, ultimately resulting in disseminated intravascular coagulation (DIC) and
severe hypoperfusion. The ultimate consequences of this excessive inflammatory
response are acute coagulopathies and the failure of multiple organ systems (Figure 1.1).
Even if effective antimicrobial therapy is initiated, the inflammatory cascade will not
abate. Its effects can be likened to a line of dominoes. The first domino to fall, injury or
infection, will set a chain reaction in motion. Even if the first domino is set back up
(treatment of the initial insult) the subsequent dominoes (the inflammatory cascade)
continue to fall.

4

Figure 1.1: General progression of sepsis from gram-negative bacterial
infection.
Infection via gram-negative bacteria leads to the release of its endotoxin LPS. LPS
molecules are then bound by LPS-binding protein (LBP). The LPS molecule is transferred
from LBP to CD14 on the surface of a macrophage. CD14 then presents the endotoxin to
the transmembrane signaling complex, Toll-like receptor 4 (TLR4). This activates a signal
cascade resulting in the release of cytokines. The action of cytokines and other
inflammatory mediators cause hypoperfusion and full activation of the coagulation cascade.
These disorders result in multiple organ system failure and severe coagulopathies.
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1.2.1 THE INFLAMMATORY RESPONSE SIGNAL CASCADE
The effectiveness of the innate immune system’s response is in part due to its
ability to amplify its response to pathogens (16). The detection of pathogens by the innate
immune system depends on a series of proteins, each performing specialized roles. These
proteins include LBP, which functions as a carrier protein for LPS monomers, CD14, the
key host cell surface receptor responsible for binding endotoxins and initiating the innate
immune response, and the Toll-like receptors, which initiate the intracellular signaling
cascade in response to specific endotoxins (17-19). Although CD14 is able to bind
endotoxins with high affinity, it is unable to further transduce the signal since it is not a
transmembrane protein. It must complex with one or more of the Toll-like receptors,
which possess transmembrane domains, allowing it to stimulate the cell’s immune
response. Like CD14, Toll-like receptors (TLRs) recognize specific molecular patterns
that are present in microbial and bacterial components. Currently, eleven human TLRs
have been identified, all sharing several common features such as an extracellular domain
consisting of multiple leucine-rich repeats and a cytoplasmic Toll/IL-1 receptor domain
(TIR) (20, 21).

Each TLR recognizes specific structural components of bacterial,

microbial, or viral pathogens and induces an immune response (22). It has been observed
that CD14 complexes with different TLRs depending on the endotoxin ligand bound and
up-regulates the level of immune response (20, 21).

Although TLRs can bind the

endotoxins directly, CD14 is essential to increase the sensitivity of response to
endotoxins by as much as 1000-fold (20, 21). In the case of gram-negative endotoxin,
LPS, CD14 complexes with TLR4, and in the case of the gram-positive endotoxin, LTA,
6

it associates with a heterodimer of Toll-like receptor 2 (TLR2) and Toll-like receptor 6
(TLR6) (23-27). The differentiation between endotoxins by CD14, and therefore the TLR
to which it delivers the endotoxin, is significant in that sepsis cases can present
differently from a clinical standpoint based on whether the causative organism is gramnegative or gram-positive (16). The up-regulation of the immune response is
accomplished in part by CD14’s high affinity for endotoxin, which enables it to detect
and bind endotoxins at concentrations significantly lower than those detected by the
TLRs (28). As briefly described earlier, this response is initiated by the binding of
endotoxin by CD14. The endotoxin LPS is first recognized by the high affinity LPSBinding Protein, which disaggregates a single LPS molecule and transfers it to CD14.
The CD14-LPS complex is then presented to TLR4 and its adaptor protein MD-2. In the
case of LTA, CD14 binds it and presents it to a heterodimer of TLR2 and TLR6 to
initiate the immune response (25, 27, 29). TLR2 is also able to respond to a variety of
other bacterial lipoproteins, either on its own or by forming a heterodimer with another
TLR (22, 30).

Once CD14 has transferred the endotoxin to its specific TLR, the

intracellular signal cascades are fairly similar.
Upon activation of a TLR, there are two main signaling pathways. These
pathways differentiate after the initial activation of the highly conserved intracellular
domain of the TLRs, the Toll/IL-1R (TIR) domain. The pathways are distinguished by
the TIR adaptor proteins recruited to the activated TIR domain. The pathways are the
MyD88 (myeloid differentiation primary-response protein 88)-dependent signaling
pathway, which is common to all the TLRs, and the MyD88-independent signaling
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pathway, which is specific to TLR4 and TLR3 (31).
The MyD88-dependent signal cascade leads to the activation of NF-κB (nuclear
factor-κB) (Figure 1.2). Activation of NF-κB allows it to enter the nucleus and induce
the expression of multiple target genes, such as tumornecrosisfactor-alpha (TNF-α) ,
interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), and interleukin-12 (IL-12),
(19, 31-34). In addition, the MyD88-dependent signaling path leads to the activation of
mitogen-activated protein kinases (MAPK), which leads to the production of nitric oxide
and additional inflammatory mediators (35).
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Figure 1.2: Toll-like Receptor MyD88-dependent and MyD88-independent signaling
cascade.
In the MyD88-dependent signal path, the stimulation of TLR4 by LPS, begins with the
transfer of LPS from LBP to CD14 then to the TLR4-MD-2 complex, triggering the association
of MyD88 with the TLR’s highly conserved cytoplasmic domain. This also occurs upon transfer
of LTA from CD14 to the TLR2/TLR6 heterodimer. MyD88 activation causes association of
TIRAP, and the recruitment of IRAK4 by MyD88. Activation of IRAK4 allows the association of
IRAK1. IRAK4 then induces the phosphorylation of IRAK1. TRAF6 is then recruited to the
receptor complex by associating with phosphorylated IRAK1. TRAF6 then dissociates from and
forms a complex with TAK1, TAB1, and TAB2 translocates to the cytosol. This leads to the
activation of TAK1. TAK1, in turn, phosphorylates both MAPK and the IKK complex, consisting
of IKK-α, IKK-β and IKK-γ. The IKK complex then phosphorylates IκB, which is subsequently
degraded. This allows NF-κB to translocate to the nucleus and induce the expression of its target
cytokine genes. The MyD88-independent signal path starts with the association of TRIF and
TRAM to stimulate TLR4’s cytosolic domain. TRIF activates the non-typical IKKs IKK-ε and
TBK1. IKK-ε and TBK1 mediate activation of IRF3, which moves into the nucleus and induce
activation of IFN-β and type I IFN inducible cytokines.
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Activation of the MyD88-independent signaling pathway leads to activation of
interferon-β IFNβ) and IFN-regulatory factor 3 (IRF3) resulting in the release of
cytokines (Figure 1.2). Rather than MyD88, the adaptor proteins recruited to the
activated TIR domain are TRIF (TIR-domain-containing adaptor protein inducing IFN-β)
and TRAM (TRIF-related adaptor molecule) (19). This pathway also utilizes the nontypical IKKs IKK-ε and TBK1 (TRAF-family-member-associated NF-κB activator
(TANK)-binding kinase 1) to mediate activation of IRF3, which upon translocation to the
nucleus activates transcription of type I IFN genes (31).
The net affect of these signal cascades is activation of a robust inflammatory
response, and as illustrated by the variety of alternate and complementary paths in this
cascade, the response can be generated with ease. The initial rate-limiting step to the
generation of an immune response is at the cell surface rather than at some point in the
intracellular signal cascade. A TLR’s ability to generate a response is restricted by its
ability to locate and bind its respective ligand. This highlights the critical importance of
CD14 in recognizing and presenting ligands to the appropriate TLR in a rapid and
specific manner. CD14 can perform all these functions through its ability to bind a wide
variety of ligands with high affinity as well as with specificity.

1.3 BACTERIAL ENDOTOXINS
1.3.1 GRAM-NEGATIVE ENDOTOXIN
The endotoxin from gram-negative bacteria is the amphipathic cell wall
component lipopolysaccharide. LPS is found in the outer leaflet of the outer membrane,
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and covers approximately 75% of the outer membrane of gram-negative bacteria (36).
The LPS molecule is composed of the O-antigen polysaccharide, the core
oligosaccharide, and the hydrophobic anchor known as lipid A (Figure 1.3) (37). The Oantigen is the most distal portion of the LPS molecule, and is exposed on the cell surface.
The O-antigen is a heteropolysaccharide composed of multiple oligosaccharide units,
containing a wide variety of both typical and atypical sugars as well as variants of those
sugars (38, 39). The O antigen displays significant levels of variation in the types of
sugar residues it contains, their organization within the repeating unit(s), and in the bonds
within and between the repeating unit(s). This makes the O antigen polysaccharide the
most variable portion of an LPS molecule (39, 40). Because of the inherent complexity
and variability contained in the O-antigen, it is the basis of classification between
serotypes in a bacterial species; some species have significant variation in the O antigen’s
polysaccharide composition and structure, such as E. coli which has ~170 different
serotypes (40).
The core oligosaccharide consists of an inner and outer core region (Figure 1.3).
It is much less variable in its composition than the O-antigen, and normally contains 15
or fewer sugar residues (36). The inner core is the portion forming the attachment point
with the hydrophobic lipid A moiety, and the outer core is the portion to which the Oantigen polysaccharide is attached. The inner core retains a more highly conserved
structure between bacteria serotypes. This is believed to result from the impact of lipid A
and the inner core in membrane integrity (40). The outer core displays greater structural
diversity. However, despite this diversity, the overall extent of structural differences seen
11

across the core oligosaccharides of a particular species or genus is still fairly limited (36,
40).
Lipid A is a glycophospholipid with a structure typified by that of E. coli’s lipid A
structure. Lipid A is composed of a 1, 4’-bisphosphorylated D-glucosamine disaccharide
backbone linked by a β(1’Æ6) glycosidic bond, with four ester linked R-3hydroxymyristic acid substituents. The hydroxymyristic acid substituents are attached at
the 2, 2’, 3, and 3’ positions with secondary acylation on the 2’ and 3’ acyl chains
(Figure 1.3). The secondary acylation of the 2’ and 3’ anchored acyl chains form
acyloxyacyl moieties with the 3’ R-3-hydroxymyristic acid’s secondary acylation being a
myristic acid and the 2’ R-3-hydroxymyristic acid having a lauric acid attached (40, 41).
Lipid A is the smallest immunostimulatory portion of LPS required to elicit a full
immune response from a host (42). In addition, the minimal LPS structure required for
cell survival is lipid A plus the Kdo (3-deoxy-D-manno-oct-2-ulosonic acid) domains,
which are the first two residues of the inner core (Figure 1.3) (43, 44). Lipid A has a
much higher level of structural conservation throughout gram-negative bacteria than any
other portion of LPS, regardless of whether a specific bacterium is considered pathogenic
or not (40). Interestingly, lipid A in its standard hexaacylated form is a powerful agonist
of the immune system, but removal of the secondary acyl chains from the acyloxyacyl
moieties produces Lipid IVa, a tetraacylated lipid A precursor, which is a potent
antagonist, blocking the response to LPS (Figure 1.3)(45, 46).
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Figure 1.3: Chemical schematic of Lipopolysaccharide, Lipid A, and antagonistic
Lipid IVa.
The numbering scheme for lipid A’s headgroup and acyl chains is shown. The acyl chain
numbering of lipid IVa is also shown. The circled numbers at the terminus of the acyl chains
indicate the acyl chain length.
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Atypical lipid A structures generally have alterations to the length of the acyl
chain(s), loss or gain of acyloxyacyl groups, and in rare cases, derivatization of an acyl
chain(s). In addition, atypical lipid A forms can also have extra sugar residues attached to
the customary glucosamine disaccharide backbone of lipid A (40). However, whether a
lipid A’s structure is standard or atypical, the phosphate groups and acyloxyacyl groups
are the key features giving lipid A its endotoxic ability to illicit an immune response (37,
40, 47).
1.3.2 GRAM-POSITIVE ENDOTOXIN
Gram-positive bacteria have no LPS, and the identity of an immunogenic
molecule from gram-positive bacteria has, over the years, been a subject of debate, with
the main candidates for the role being peptidoglycan (PGN), and lipoteichoic acid (LTA).
Lipoteichoic acid is an amphiphilic molecule found in gram-positive but not in
gram-negative bacteria. LTA’s structure is composed of a hydrophilic backbone
consisting of polyglycerophosphate repeating units, and substituted with D-alanine,
glucosamine, and hydroxyl groups. The polyglycerophosphate backbone is attached to a
gentiobiosyl-diacylglycerol lipid anchor which secures the molecule in the membrane
(Figure 1.5) (48).

The number of glycerophophate units that make up the

polyglycerophosphate backbone varies between bacterial species. For example,
Staphylococcus aureus (S. aureus) averages 40-45 glycerophosphate units whereas
Bacillus subtilis (B. subtilis) averages only 22-25. It has been shown that the more Dalanine substituents found on the polyglycerophosphate chain of an LTA the greater the
immune response initiated. This is illustrated by the LTA of S. aureus, where D-alanine
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represents 70% of the total substituents on the polyglycerophosphate chain, versus B.
subtilis, with D-alanine accounting for only 25% of the substituents on its
polyglycerophosphate chain (49, 50). Despite the variation in the number of repeating
units in the polyglycerophosphate chains of S. aureus and B. subtilis, the structure of their
lipid anchors is essentially identical. The lipid anchor of both species is composed of a
gentiobiose headgroup, with two acyl chains linked to the headgroup through a glycerol
(Figure 1.4). The lone difference in their lipid anchors is that on average S. aureus’s acyl
chains are two carbons longer than those of B. subtilis, 16 versus 14 (49, 50).
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Figure 1.4: Structural schematic of Lipoteichoic acid.
The potential polyglycerophosphate substituent’s sites are indicated by R. The circled numbers at
the terminus of the acyl chains indicate the acyl chains length.
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In recent years, there has been progress towards resolving the controversy over
which gram-positive cell wall component is the source of immunostimulation.
Peptidoglycan has been excluded as a ligand for any TLR pathway. It was proven that the
early identification of PGN binding by TLR2 was due to sample contamination with
significant levels of lipopeptide, teichoic acid, and lipoteichoic acid left behind by the
methods employed to extract PGN from native cell membranes (50, 51). It has now been
conclusively proven that PGN is not a ligand for TLR2 or any of the TLR2 heterodimer
(51-54). The argument against LTA being the immunostimulator from gram-positive
bacteria was established based simply on conflicting results of immune response
generation in cell based assays (51, 53). The failure of LTA to produce a strong immune
response was traced back to the extraction and purification of the LTA from native cell
walls. It was discovered that traditional extraction of LTA using a 68 ºC phenol-water
mixture resulted in the release of the labile D-alanine substituents off of the backbone,
and could even result in the loss of multiple glycerophosphate units (49, 50). Production
of synthetic LTA has confirmed that LTA generates an immune response through
TLR2/6 (26, 52). In addition, it was shown that the LTA lipid anchor with five
glycerophophate units and carrying four D-alanine substituents and a single Nacetylglucosamine is the minimum LTA structure necessary for initiating an innate
immune response (55, 56).

1.4 CD14
CD14 is the key high-affinity receptor for bacterial endotoxins and serves a
critical role in endotoxin-induced activation of innate immune cells (57). CD14 is a
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necessity to achieving rapid activation and up-regulation of the immune response to
bacterial or microbial incursion. It has been hypothesized that CD14 recognizes/binds
LPS and LTA via recognition of pathogen-associated molecular patterns, which are
common structural elements found in endotoxins (58). CD14 is required for the response
to low concentrations of LPS (57, 59). This is illustrated by the fact that CD14-deficient
mice are insensitive to LPS and are essentially unaffected by LPS doses lethal to wildtype mice (59).
In humans, CD14 is a glycoprotein constitutively expressed in a 55 kDa
membrane bound form (mCD14), found mainly on the cell surface of monocytes and
macrophages anchored to the membrane through a glycosylphosphatidylinositol anchor
(GPI-anchor) (60). Additionally, mCD14 is found to a lesser extent on the surface of a
variety of other immune cells including polymorphonuclear neutrophils, chondrocytes, B
cells, and dendritic cells (12). CD14 is also present in a 48 kDa soluble form (sCD14)
typically found in serum and body fluids of healthy adults at concentrations in the range
of 2-6 µg/ml. In patients with sepsis, the circulating levels of sCD14 in the plasma can
exceed 7 µg/ml (61-64). The soluble form of CD14 is nearly identical to mCD14, the
exception being its lack of a GPI anchor (61). It is thought that sCD14 is produced in vivo
either by cleavage of mCD14 via proteases and phospholipases from the cell surface of
monocytes and macrophages, or as a secreted protein without the necessary posttranslational modification needed for attachment of the GPI-anchor (60, 62, 63). The
GPI-anchor is not required for CD14 function or signaling. It is thought that the
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anchoring of CD14 to the membrane may simply facilitate the localization of mCD14 in
close proximity to the membrane spanning TLRs (65, 66).
Both the soluble and membrane bound forms of CD14 signal through the same
TLR pathways. A significant difference is that the presence of sCD14 allows cells that do
not express mCD14, such as some endothelial and epithelial cells, to respond to lower
levels of endotoxin than could be detected by the cell’s endogenous TLRs alone (67-69).
Another difference between the mCD14 and sCD14 initiated response to endotoxin was
seen in the sensitivity of LPS detection. Wild-type murine monocyte cells, which express
mCD14, are capable of inducing pro-inflammatory cytokine production with only 1
ng/ml concentrations of LPS present. In contrast, CD14-deficient murine monocytes
supplemented with 20 µg/ml recombinant full-length sCD14 did not induce cytokine
production until the LPS concentration was at least 100 ng/ml. This difference is
insignificant considering that with no CD14 present it takes over 1 µg/ml of LPS to see
even minor activation of cytokine production (59). This decrease in sensitivity is likely
due to the fact that mCD14 is generally located in very close proximity to TLR4
signaling complexes, allowing a speedy transfer LPS to TLR4 and a rapid triggering of
the response (35). However, sCD14 has the additional task of first locating a TLR4
signaling complex then transferring the LPS to it before the cytokine induction can be
initiated.
1.4.1 CD14 STRUCTURAL FEATURES
The full-length cd14 gene codes for 375 amino acids, the first 19 amino acids
compose a transport signal sequence that is cleaved off in the endoplasmic reticulum to
19

yield the mature 356 amino acid mCD14 protein. In addition, the mature soluble form of
CD14 also lacks the last eight C-terminal amino acids, which are lost in the cleavage of
the GPI anchor (61). Since both mature forms of CD14 lack the signal peptide, it is
customary to number the amino acid sequence at the first N-terminal residue after the
secretion signal. As a member of the leucine-rich repeat family of proteins, which also
includes the TLRs, CD14 contains 10 leucine-rich repeats spanning from residue 67-312
(70). The leucine-rich repeat (LRR) motif is typically a 20 to 29-residue sequence with
characteristically positioned hydrophobic residues (71). As implied by its name, the
predominant hydrophobic amino acid being repeated in an LRR is leucine. However,
isoleucine, valine, and phenylalanine can also occupy the role of “leucine” in the
repeating pattern of an LRR (72). In the case of human CD14, the repeated pattern is
LXXLXLX, where X is any amino acid and L is Leu, Val, Phe, or Ile (73).
CD14 also has four N-linked glycosylation sites. Cleavage of the glycosylations
using glycosidases results in a ~12 kDa decrease in molecular weight, indicating that
glycosylations account for roughly 20% of CD14’s total molecular weight (74). Within
the last several years, a crystal structure of full-length murine sCD14 without a ligand has
been solved (Figure 1.5) (75).
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Figure 1.5: Crystal structure of full-length murine soluble CD14.
Ribbon view of secondary structural elements in full-length murine sCD14 (Protein Data Bank
code 1WWL) (75). A representative region of the α/β-fold is indicted by the arrows. The 11
leucine-rich repeats (LRR) found in mouse CD14 are numbered, and the hydrophobic amino
acid repeating sequence (LXXLXLX) is colored blue for each LRR. Figure generated using
PyMol (Delano Scientific, San Carlos, CA).
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The X-ray crystal structure shows that CD14 has an overall α/β-fold containing a mixture
of α-helical and β-sheet secondary structure connected by loops of varying length; the
vast majority of the protein’s secondary structural elements are β-sheets. In addition, the
crystal structure has a general shape reminiscent of half a horseshoe with a series of βsheets forming the concave inner edge, and a combination of loops and a few α-helices
forming the outer convex edge. This general architecture is typical of leucine-rich repeat
proteins as has been shown by the crystal structures for several other members of the
LRR-protein family, such as the Yersinia pestis cytotoxin YopM and more recently the
structures of several TLRs and TLR complexes (29, 76-78). The crystal structure also
revealed a large hydrophobic pocket surrounded by a largely hydrophilic rim at the Nterminus (75). Murine CD14 shares ~66% sequence identity with human CD14 which
makes the mouse crystal structure a useful structural reference for comparison to human
CD14 (73). An important finding made while investigating the functional roles of the
leucine-rich repeats was that a 152 residue N-terminal truncation, which eliminated all
but the first 3 repeats, still retained the ability to bind LPS as well as full biological
activity on par with that of wild-type sCD14 (Figure 1.6). The fact that even when
lacking repeats 4 through 10 CD14 retained wild-type function suggests that the last 7
repeats are not critical for CD14 binding or activity (70, 79). At this time the biological
function of these repeats is not known. It has been hypothesized that the presence of all
10 repeats serve as a structural scaffold to orient or position membrane bound CD14 in
such a way that facilitates ligand transfer to the transmembrane TLRs, which have the
same general structure as CD14 but contain from 19 to 25 LRRs in their extracellular
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domains (71). LRRs are known to play a role in protein-protein interactions, as illustrated
by the recent crystal structures of the TLR1-TLR2 heterodimer, and the TLR3
homodimer complexes (29, 80). Though both CD14 and the TLRs contain LRRs, their
contribution to the formation of a CD14-ligand-TLR complex is not known. This
complex is so transient that it has yet to be stably isolated for any CD14-TLR complex,
preventing detailed characterization of its protein-protein interactions (28, 81). In
addition, LRRs are also involved in ligand binding interactions (82). However, given the
thousands of protein sequences identified as containing LRRs the primary function of
LRRs appears to be as a versatile framework, facilitating protein-protein interactions
(72). In the time since murine CD14’s structure was solved, the structures of LRR-protein
family member’s TLR3, the TLR4/MD-2 complex, and the TLR1-TLR2 heterodimer, all
of which are receptors in the innate immune response, have had their structures solved
and each display a similar overall architecture to that of murine CD14 (29, 77, 78, 83,
84).
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Figure 1.6: Homology Model of the 152-residue N-terminal truncation of human
soluble CD14.
Ribbon view of secondary structures of human sCD14 illustrating the hydrophilic rim and
hydrophobic pocket. β-sheets are shown in yellow, and α-helices are in red. Homology model
made by Wei Zhang. Figure generated using PyMol (Delano Scientific, San Carlos, CA).
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1.4.2 CD14 LIGAND BINDING
CD14’s ability to recognize a wide assortment of ligands led to the hypothesis
that CD14 is a pattern recognition receptor, which recognizes its ligands via pathogenassociated molecular patterns (PAMPs) (17). The utilization of pattern recognition
receptors to recognize and initiate an innate immune response is well conserved even
among different species, from plants and insects to mammals (22). Pattern recognition
receptors are thought to recognize molecules and structures unique to bacteria and
microbes that are not associated with a host’s cells. These unique molecules share
common structural features and are termed pathogen-associated molecular patterns.
PAMPs consist primarily of microbial cell wall components that are essential for the
microorganism’s survival. The essential nature of a PAMP to cell survival means that its
general structural characteristics are conserved, as changes to the structure would be
difficult without detrimentally influencing an organism’s survivability (22). This critical
role in the organism’s survival is illustrated by well-characterized PAMPs from several
organisms as illustrated by lipid A in gram-negative bacteria and lipoteichoic acid in
gram-positive bacteria, both of which are critical for membrane integrity (85). This is
also seen for the viral PAMP, double stranded RNA, which is produced by RNA viruses
during their replication (86). The essential and conserved role of PAMPs in cell survival
is true even for PAMPs recognized by the plant innate immune system. In plants, the
best-characterized PAMP is flagellin, the principal building block of the bacterial flagella
(87). Flagellin is recognized by flagellin-sensing 2 (FLS2) in Arabidopsis and by TLR5
in mammals (88). The direct interaction of flagellin with a LRR in TLR5 relies strongly
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on electrostatic interactions as indicated by mutagenesis studies (89-91). The direct
interaction of flagellin with FLS2 from Arabidopsis thaliana, has been shown to be
sensitive to salt concentrations, which is indicative of ionic interactions (92). At this time,
these investigations represent the most detailed structural studies carried out to date on
the flagellin binding interactions of FLS2 and TLR5. The role of ionic/electrostatic
interactions in ligand binding has also been seen in the binding of LPS by CD14, as
evidenced by charge reversal mutagenesis studies, which caused CD14 to become unable
to bind LPS (93, 94).
CD14 is capable of binding well over a dozen ligands (Table 1), and with its
ability to bind atypical structural variants of lipid A and LTA, this number could be even
larger (25, 95-106). While the binding affinities for most of the ligands in Table 1 hasve
not been determined, the affinity of those that have been determined range from 27 nM
for LPS to 5.7 µM for a synthetic triacyl lipopeptide (Pam3CSK4) (98, 102). CD14’s
ligand binding and recognition is all the more remarkable in that identification and
characterization of CD14’s binding site revealed that it possesses a single binding pocket.
The residues/regions identified in CD14 as necessary for the binding of LPS are
primarily located within a region spanning from the N-terminus to residue 100.
Introduction of a combination of single and multiple deletions into CD14’s N-terminus
revealed that several hydrophilic regions and amino acids are required for serum
dependent binding of LPS (107). Additionally, a group of amino acids spanning residues
57–64 was found to be protected from protease digestion when LPS was bound by CD14.
Deletion of this group of amino acids resulted in a loss of binding ability as well as the
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ability to initiate a response to LPS (108, 109).
Another region of amino acids, residues 39–44, was found to function in LPS
binding through an alanine scanning mutagenesis study (110). The contributions of
individual hydrophilic amino acids in the N-terminus were further examined by means of
serine replacement mutagenesis and charge reversal mutations (93, 94). Only the charge
reversal mutations resulted in a loss of LPS binding ability by CD14. Another study
identified an LPS-binding domain in CD14 located in the region adjacent to the Nterminal 66 amino acids, by mapping the full-length 356 amino-acid CD14 protein using
20-amino-acid peptides. This study found that a peptide containing amino acids 81-100
was sufficient to bind and neutralize LPS (111).
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Table 1. Bacterial, Microbial, Viral, and Host derived CD14 ligands
Interacting Molecule

Source Organism

Reference

Tri-acyl lipopeptides
Di-acyl lipopeptides
Lipoprotein/Lipopeptides
polymeric Peptidoglycan
Lipoteichoic acid
Lipomannan
Lipoarabinomannan
Glycoinositolphospholipids
Glycolipids
fungal cell wall components
Lipopolysaccharide
Atypical LPS
Atypical LPS
double-stranded RNA
Fusion protein
Heat Shock Protein 60

gram-positive bacteria, mycobacteria
Mycoplasma salivarium (FSL-1)
gram-positive and gram-negative bacteria
gram-positive bacteria
gram-positive bacteria
mycobacteria
mycobacteria
Trypanosoma cruzi
Treponema maltophilum
Aspergillus fumigatus
gram-negative bacteria
Helicobacter pylori
Porphyromonas gingivalis
viruses
Respiratory syncytial virus
Host

(95)
(96)
(96)
(97)
(25)
(98)
(98, 112)
(99, 113)
(100)
(101)
(97, 102)
(103)
(103)
(104)
(105)
(106)
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Based on these studies, it was concluded that the binding site was located at the
N-terminus of CD14. This was confirmed by a large hydrophobic pocket rimmed by
charged residues at the N-terminus of the mouse CD14 crystal structure (75). These
studies shed significant light on CD14’s binding mechanism(s), revealing that binding
interactions take place using a number of broad overlapping residues and regions, but
they did not examine whether the interactions were ligand specific. It bears noting that
many of the ligands CD14 binds contain fatty acids and negatively charged phosphate
groups, and that many of the amino acids identified as being involved in CD14’s binding
interactions are charged amino acids. The surrounding of the binding site by charged
residues strongly implicates ionic interactions as a critical ingredient in the binding and
recognition of endotoxins. This is validated by the fact that charge reversal mutations
resulted in a loss of function by CD14 (93, 94). This also correlates with the fact that
dephosphorylated lipid A is not bound by CD14, and that monophosphoryl lipid A has
reduced binding affinity to CD14; both of these variants result in reduced to negligible
biological activation of an immune response (114, 115). The fact that full-length CD14
has a large hydrophobic cavity created by the LRRs makes it ideally suited for
sequestering the multiple acyl chains of LPS and LTA. In combination with the charged
amino acids rimming the hydrophobic pocket (Figure 1.6), this suggests that placement
of the acyl chains in the hydrophobic pocket would result in the positioning of an
endotoxin’s sugar headgroup and its charged moieties in proximity to hydrophilic rim’s
charged amino acids. However, atomic level structural information about CD14’s binding
interactions and its differential recognition of endotoxins is limited by the fact that the
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CD14 crystal structure has no ligand.
Recently, the crystal structure of the TLR4/MD-2 co-complex has been solved
with an agonist and antagonist bound, providing a wealth of new information into
TLR4’s interaction with LPS (78). However, it is CD14’s role upstream that is central to
the enhancement of the immune responses of TLR4 and TLR2. In addition, CD14’s
mechanism of differential ligand binding has yet to be fully characterized, yet remains of
great importance.
In addition to being a pattern recognition receptor, CD14 has been proposed to
have a broader physiological role in lipid exchange mechanisms, where it catalyzes the
exchange of different phospholipids including phosphatidylcholine, phosphatidylinositol
and phosphatidylethanolamine (116). CD14 on the surface of human macrophages is also
important in the recognition and clearance of apoptotic cells (117). Due to its
multifunctional role, CD14 is now viewed as a key pattern recognition receptor in the
initiation of the innate inflammatory response. Capable of recognizing shared structural
features of microbial cell surface components, CD14 enables the host to respond to
pathogenic bacteria, but not to a great variety of other non-microbial polysaccharides.
However, the specific molecular patterns recognized by CD14 had not been determined,
as no structure for a CD14-endotoxin complex is available. This is likely because of the
many

challenges

associated

with

structural

determination

of

co-complexes.

Crystallization is further complicated by the micelle forming characteristics of LPS and
LTA, and the highly flexible nature of their glycolipid structures. This has prevented
detailed molecular level characterization and comparison of various CD14-endotoxin
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ligand complexes. NMR spectroscopy is an excellent method for characterizing
interactions between protein and ligands in complex with each other, and can provide
residue-level observation of interactions between protein and ligand.
This dissertation focused on characterizing the interactions between CD14 and the
primary gram-negative and gram-positive endotoxins, LPS and LTA, using solution
NMR spectroscopy. In this project, NMR structural studies were carried out on
isotopically labeled LPS- and LTA-based ligands to determine the structural features of
these endotoxins which interact with CD14. It is hoped that these studies will enable
further understanding of differential recognition of these endotoxins by CD14 and shed
light on the mechanistic aspects of how ligand pattern recognition by CD14 translates
into specificity of TLR selection. These studies will also benefit the design of new
ligands that can antagonize the pro-inflammatory effects of CD14 and reduce
inflammatory over-activation. Targeting of CD14 may, therefore, offer the possibility of
safely interrupting the process of systemic inflammation in response to bacterial infection
early on, slowing or preventing the severe over-activation of the inflammatory response.
This could avert the onset of sepsis, allowing serious infections to be treated without the
inflammation induced complications of sepsis.
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CHAPTER 2. EXPRESSION, PURIFICATION,
CHARACTERIZATION, AND ISOTOPIC LABELING OF
SOLUBLE CD14 AND THE ENDOTOXIN LIGANDS Kdo 2 LIPID A AND LIPOTEICHOIC ACID

2.1 INTRODUCTION
NMR spectroscopy is an excellent method for characterizing interactions between
a protein and its ligand(s) in complex with one another. The use of NMR can enable
residue-specific information to be collected regarding the interaction of the ligand on the
protein, and conversely the protein on the ligand. When a substrate or ligand is bound by
its receptor, such as a large protein, several NMR parameters can be affected. These
include the chemical shifts and the relaxation times of both the ligand and the protein.
The local environment of the bound ligand is different from the environment it
experienced in its free state; this causes the chemical shifts of its protons to change.
Because, chemical shifts are very sensitive to changes in a residue’s environment, they
can be used to detect even weak interactions, as evidenced by observable changes in the
chemical shifts. The same is true for the chemical shifts of the protein’s residues that are
affected by either direct binding interactions or indirectly as a result on other neighboring
residues involvement in the binding. Specific types of interactions can also be observed
an example being ionic or electrostatic interactions, which can correlate to chemical shift
changes in relation to pH changes, or also evidenced by the loss or gain of proton signals
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due to deprotonation of protonation of residues as the sample pH reaches their respective
pKa (118, 119). NMR can also reveal whether a binding interaction is dynamic, which is
indicated by changes in the linewidth and shape of a chemical shift relative to the rate at
which it is transitioning between various possible conformational states. These detailed
methods for examination of binding interactions and structural changes makes NMR
ideal for investigating the binding and differential recognition of endotoxins by CD14.
The projects described in this dissertation focused on characterizing the interactions
between CD14 and the primary gram-negative and gram-positive endotoxins, LPS and
LTA, using solution NMR spectroscopy.
In order to perform NMR studies of CD14, it is necessary to obtain milligram
quantities of isotopically labeled protein. For a study to be biologically relevant, it is
critical that the production of any recombinant protein for use in the research be in a
functional form with a native fold. To that end, a fully functional fragment of sCD14
consisting of the first 152 residues of the N-terminus of the protein, which includes the
region for endotoxin binding, was chosen for expression and use in these studies (70).
Throughout the remainder of this dissertation, sCD14 will refer to the soluble N-terminal
152-residue truncation of full-length sCD14 containing the endotoxin-binding domain,
unless indicated otherwise. Expression of human proteins in glycosylated forms is
inherently difficult in any system. In the case of CD14, the problem is compounded by
the fact that it has high affinities for endotoxin, and as such must be produced in a system
which contains minimal amounts of endotoxin (25, 102). In addition, to allow for NMR
studies and assignments, CD14 must be isotopically labeled. These constraints made it
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critical to select an appropriate system to express sCD14.
E. coli is capable of producing recombinant proteins in large quantities, and is a
well characterized source for the cost-effective production of isotopically labeled
samples. However, it is not capable of post-translational modification of expressed
proteins, and any CD14 produced using E. coli would have considerable endotoxin
contamination. Mammalian expression systems have been used to produce many
glycosylated human proteins. However, mammalian expression systems are unable to
produce the large quantities of isotopically labeled samples needed in a cost effective
manner. With these issues in mind, the yeast system of Pichia pastoris was chosen. As a
eukaryotic system, Pichia pastoris is capable of post-translational modifications, and
minimizes the potential endotoxin contamination. In addition, the glycosylations attached
by Pichia are short for a eukaryote consisting of only 8-14 mannose residues, making it
more amenable to solution NMR studies (120). While Pichia’s glycosylations might be
shorter they are still functional, which is important for CD14 because the N-linked
glycosylation at Asn132 is necessary for proper function. The other three N-linked
glycosylation sites can be mutated with little affect to CD14’s function (121), though we
have observed a significant decrease in the lifespan of CD14 in its folded form after
removal of all glycosylations. Pichia produced proteins can be isotopically labeled with
relative ease by simple substitution of the media with a
methanol, and/or a

13

C carbon source, such as

15

N nitrogen source, such as ammonium sulfate. Another advantage

Pichia affords is that it can be readily scaled up from shake flask to fermentation. This
combination of features made Pichia pastoris the most advantageous system for
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recombinant expression of sCD14.
In order to unravel the structural features of the endotoxin ligands necessary for
interaction with CD14, it is essential to produce pure, isotopically labeled ligands directly
from gram-negative and gram-positive bacterial sources. Given the size and inherent
heterogeneity of the O-antigen and core oligosaccharide, native LPS is undesirable for
use in detailed structural studies (40). For this reason, a minimal endotoxic portion of
LPS, Kdo 2 -Lipid A (Figure 1.3), was chosen for use. Kdo 2 -Lipid A is a wellcharacterized sub-structure of LPS capable of eliciting a strong immune response
comparable to that of whole LPS (122). The heptosyltransferase-deficient Escherichia
coli K-12 mutant, W3110 δ(rfaCF)::tet6 (WBB06), which is unable to attach the outer
core oligosaccharide and consequently also lacks the O-antigen, has only Kdo 2 -Lipid A
as its LPS (44). The WBB06 strain, (a gift from Christian Raetz, Duke University) was
utilized to produce the Kdo 2 -Lipid A samples for use in investigating the sCD14
interactions with gram-negative endotoxin. Starting from pure Kdo 2 -Lipid A, several
lipid A and Kdo 2 -Lipid A structural variants were produced (Figure 2.1) to aid in the
comprehensive investigation of the binding interactions of Kdo 2 -Lipid A with sCD14.
These variants include creation of lipid A through cleavage of the Kdo units from Kdo 2 Lipid A. Dilute acid hydrolysis of the 1-phosphate group produces the partial agonist
monophosphoryl lipid A, and complete dephosphorylation, using hydrofluoric acid,
produces a non-binding variant. Removal of the O-linked acyl chains from Kdo 2 -Lipid A
creates the partial agonist de-O-acylated Kdo 2 -Lipid A (45, 46, 123). Lipid IVa was
produced from the E. coli K-12 mutant, W3110 (kdtA::kan) pWMsbA (CMR300)
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(another generous gift from Christian Raetz, Duke University). This mutant produces
Lipid IVa as its LPS via the deletion of kdtA gene, which encodes the Kdo transferase in
conjunction with over-expression of MsbA, the inner membrane flippase for core-lipid A.
This over-expressed flippase combined with the deletion of the Kdo transferase results in
the premature flipping of Lipid IVa, which is produced normally by E. coli as a precursor
in LPS production, to the outer leaflet and prevents Kdo attachment (124). The lipid A
and Kdo 2 -Lipid A variants have been previously characterized as an agonist, or partial
agonist based on their ability to induce production of the pro-inflammatory cytokines IL1, IL-6, and TNF-α. In the case of Lipid IVa, it was classified as an antagonist based on
its ability to almost completely inhibit cytokine induction by LPS (125, 126).
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Figure 2.1: Agonist and Antagonist partial structures of Kdo 2 -Lipid A, Lipid A,
and Lipoteichoic acid partial structures.
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LTA was produced using Bacillus subtilis, whose LTA shares many features in
common with the highly immunogenic LTA of Staphylococcus aureus, but as a biosafety
level 1 organism, B. subtilis does not require any additional safety procedures while S.
aureus, a level 2 organism, does. The LTA of S. aureus is considered to be the structural
archetype of immunogenic LTA, but B. subtilis differs in only two ways from that of S.
aureus. These differences are limited to the polyglycerophosphate chain, which in S.
aureus has 40 to 45 glycerophosphate repeating units versus B. subtilis’s 25 to 28. The
second difference is in the percentage of polyglycerophosphate substituents that are Dalanine. In S. aureus D-alanine represents 70% of the total substituents on the chain, but
in B. subtilis D-alanine accounts for only 25% of its total (49, 50). However, the lipid
anchor portion of both S. aureus and B. subtilis’s LTA are identical, and both species
full-length LTAs induce very similar levels of TNF-α production in human whole blood
(50). For these reasons, and because of the ease of culturing B. subtilis in minimal
mediums in isotopically labeled forms, B. subtilis was selected for production of LTA
samples. In addition to producing full-length B. subtilis LTA, the polyglycerophosphate
chain was cleaved to produce the partial agonist LTA lipid anchor. The LTA lipid anchor
is characterized as a partial agonist based on its lower levels of TNF-α induction
compared to the levels induced by full-length LTA (56).
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2.2 MATERIALS AND METHODS
2.2.1 DESIGN OF SOLUBLE CD14 CONSTRUCT
The gene sequence encoding the N-terminal endotoxin binding domain of human
sCD14, consisting of the 152 residues after the signal peptide sequence (20–171), was
synthesized with codon-optimization for yeast and inserted into the Pichia expression
vector pPICZαA (Invitrogen, Carlsbad, CA) by BIO S&T (Montreal, Canada). The
pPICZαA vector contains a zeocin antibiotic resistance gene, the αfactor secretion signal,
to allow secretion of the inserted gene product into the culture medium, and a 6x histidine
tag to aid in purification. Additional plasmid was produced using E. coli BL21 cells from
Promega (Madison, WI). E. coli growth, plasmid isolation, and purification were all
carried out using standard molecular biology techniques and miniprep and reaction cleanup kits from Qiagen (Valencia, CA). Plasmid DNA was sequenced by the Molecular
Biology Research Facility (MBRF) on the University of Tennessee campus to confirm
the sequence, proper insertion, and location of the 152-residue CD14 gene sequence
within pPICZαA. Sequencing was preformed in both the 5’ and 3’ directions using the 5’
AOX1 and 3’ AOX1 sequencing primers described in the Easyselect™ Pichia Expression
Kit manual (Invitrogen).
2.2.2 TRANSFORMATION OF Pichia pastoris
The purified pPICZαA-CD14 construct must be linearized prior to transformation
into Pichia. Linearization was carried out using the restriction enzyme SacI (Promega,
Madison, WI), and was performed per the manufacturer’s guidelines. The linearization
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was checked via gel electrophoresis on a 1.2 % agarose gel containing 0.48 µg/ml of
ethidium bromide.
The lineraized pPICZαA-CD14 construct was transformed into the wild type
Pichia pastoris strain X-33 (Invitrogen) using an optimized electroporation method
developed in our lab, combining portions of the protocols described in Wu and
Letchworth (127), De Backer et al. (128), and the Easyselect™ Pichia Expression Kit
manual. X-33 was streaked out from a stab onto Yeast Extract Peptone Dextrose Medium
(YPD) plates containing 100 µg/ml ampicillin and allowed to grow overnight at 30 °C.
The next day, a single colony from the plate was inoculated into YPD liquid medium
containing ampicillin and allowed to grow until it reached an OD 600 of between 1.3 and
1.5. Then 50 ml of culture was spun down at 1500g for 5 minutes in a chilled tube and
resuspended in 50 ml of ice-cold sterile water. Following a second centrifugation step,
the cell pellet was resuspended in 25ml of cold water and spun again. The cell pellet was
then resuspended in 4 ml of a solution containing 100mM lithium acetate, 10 mM DTT,
0.6 M sorbitol, 10 mM Tris-HCL pH 7.5, and incubated for 30 minutes at room
temperature. After this incubation, the cells were centrifuged and resuspended in 2 ml of
ice-cold sterile 1M sorbitol, followed again by centrifugation and resuspension in 150 µl
of 1 M sorbitol. An 80 µl volume of cells were placed in a chilled 1.5 ml microtube and
0.5-1 µg of linearized DNA was added to the cells. The cells and DNA were incubated on
ice for 5 minutes before being transferred into an electroporation cuvette with a 2 mm
gap. This was immediately placed into a BioRad micropulser electroporator and pulsed
with 2 kV using the preset Pichia parameters in the instrument. Immediately post
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electroporation, 0.9 ml of 1 M sorbitol was added to the cuvette. The contents of the
cuvette were then transferred to a sterile 1.5 ml microtube and allowed to recover for 1
hour at 30 ºC. After recovery, the cells were inoculated onto Yeast Extract Peptone
Dextrose Sorbitol Medium (YPDS) plates containing 100 µg/ml of zeocin and allowed to
incubate at 30 ºC for 3-5 days or until colonies appeared.
2.2.3 SCREENING OF Pichia pastoris CLONES FOR HIGH EXPRESSION
Pichia transformants express protein at differing levels based on the number of
copies of the transformed construct integrated into the Pichia’s genome. The higher the
number of copies, the higher the expression levels of recombinant protein as well as the
higher the resistance to zeocin. Initial screening for high expressing transformants was
carried out by spotting of 52 individual colonies onto gridded YPD plates containing 1
mg/ml zeocin. After two days of growth at 30 ºC, each colony was analyzed for its ability
to grow on the 1 mg/ml zeocin plates. Colonies showing the healthiest/most robust
growth were selected for secondary screening.
Secondary screening consisted of growing the colony in 12 ml of YPD medium
overnight, followed by transfer into 4 ml of the expression medium, buffered methanolcomplex medium (BMMY) containing 0.5 % methanol (v/v). The culture was allowed to
grow for 72 hours with a total of 0.75 % methanol added approximately every 24 hours.
After 3 days of growth in expression media, the cultures were spun down and a 2 μl
portion of unconcentrated supernatant from each colony was run on an SDS-PAGE gel.
The SDS-PAGE was silver stained, and the best expressing colony was identified based
on which colony had the largest sCD14 band. The position of the sCD14 band in the
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SDS-PAGE was initially confirmed via western blotting. The sCD14 band in subsequent
SDS-PAGE screening gels was identified by position as it was the dominant band on the
gel, and distinctly positioned in relation to the molecular weight marker.
2.2.4 EXPRESSION AND PURIFICATION OF SOLUBLE CD14
Large-scale shake-flask expression of sCD14 took place using 2.8 L Fernbach
flasks. A single loop from a glycerol stock of the highest expressing sCD14 colony was
streaked onto a 200 mg/ml zeocin YPD plate and allowed to grow for two days. Several
individual colonies were then selected and inoculated into 15 ml of YPD. After growth
overnight, the 15 ml culture was used to inoculate a 125 ml of YPD. This 125 ml culture
was grown overnight, and the following day used to inoculate 1L of YPD. The 1 L YPD
growths were allowed to grow to an OD 600 of 5-8, approximately 20-24 hours, at which
time the cultures were spun down. The cell pellet was then resuspended in 250 ml of the
expression media, BMMY, and 0.75 % (v/v) of methanol was added every 24 hours.
After ~96 hours in BMMY media, the culture supernatant was harvested via a multistep
centrifugation process. Isotopic labeling was accomplished by simply substituting the
unlabeled methanol and ammonium sulfate in BMMY for

13

C methanol, and

15

N

ammonium sulfate.
The culture media supernatant was passed through an IMAC column packed with
~3 ml of Talon Cobalt Metal Affinity Resin (Clontech, Mountain View, CA). The
column was washed with 100 ml of PBS, pH 7.4 containing 1M NaCl to remove
nonspecific binders. Then 40 ml of 20 mM imidazole in PBS pH 7.4 was used to elute
weakly binding proteins, followed by 40 ml of 125 mM imidazole in PBS pH 7.4 to elute
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tightly bound proteins. The imidazole elutes were then concentrated down to 1.5 ml and
loaded onto a HiPrep S-100 Sephacryl column (GE Healthcare). The column was run at
0.5 ml/min in PBS pH 7.4. The resulting pure sCD14 peak eluted from the column at
~65 ml and individual 1 ml fractions were stored at -80 °C.
2.2.5 GROWTH, EXTRACTION, AND PURIFICATION OF Kdo 2 -LIPID A
Production of Kdo 2 -Lipid A was accomplished by use of the E. coli mutant
WBB06, which was grown in M9 minimal medium at 37 °C with agitation. One liter of
M9 medium contained 7 g Na 2 HPO 4 , 3.5 g KH 2 PO 4 , 0.5 g NaCl, 1 ml trace metals
solution, 4 g D-glucose, 1 g NH 4 Cl, and 12 μg/ml tetracycline. To obtain isotopically
labeled samples 13C 6 D-glucose and 15NH 4 Cl were substituted in place of their unlabeled
versions. After 22-24 hours the cell pellet was harvested by centrifugation, and the cell
pellet was then stored at -80 ºC until needed.
Prior to extraction of the Kdo 2 -Lipid A, the cell pellet was resuspended and
washed with endotoxin-free water and then washed twice with anhydrous ethanol. The
washed pellet was inverted and allowed to drain for ~10 minutes. A monophasic
extraction solution containing liquid phenol, chloroform, and petroleum ether in a ratio of
2:5:8 (v/v) was added to the cell pellet in a ratio of 4 ml extraction solution per 1 gram of
cell pellet. The cell pellet-extraction solution mixture was then vortexed and sonicated
until a fine solution was produced. The cell pellet-extraction solution mixture was then
sealed tightly and left stirring overnight at room temperature. Next, the extraction mixture
was centrifuged at 15,000 rpm for 10 minutes, and the supernatant was saved. The pellet
was re-extracted once more for 2-3 hours and centrifuged again. The supernatant from
43

both extractions was pooled and filtered into a round bottom flask. Petroleum ether and
chloroform were removed via rotary evaporator; deionized water was added dropwise to
the remaining liquid phenol in the round bottom flask to precipitate the Kdo 2 -Lipid A
(129).
The precipitate was collected by centrifugation and resuspended by vortexing and
sonication in 0.2 M NaCl, which causes Kdo 2 -Lipid A to aggregate; the round bottom
flask was also washed and sonicated with several ml of 0.2 M NaCl and this was pooled
with the resuspended precipitate. The supernatant was then ultracentrifuged at 30,000
rpm for 15 minutes to concentrate the Kdo 2 -Lipid A. The resulting supernatant was
poured off the pelleted Kdo 2 -Lipid A before being resuspended in 1.5 ml of fresh 0.2 M
NaCl. This sample was then loaded on a HiPrep Sephacryl S-100 column, using 0.2 M
NaCl running buffer, and with UV detection at 254 nm (130). The Kdo 2 -Lipid A micelle
eluted as a single peak in the void volume of the column. The center peak fractions were
combined, placed in an ultracentrifuge tube, and diluted with endotoxin-free water. The
combined fractions were then centrifuged at 50,000 rpm for 15 minutes. This was
followed by repeated resuspension and centrifugation steps, until the Kdo 2 -Lipid A pellet
was a uniform hazy, clear-white color. The sample’s identity and purity were then
confirmed by NMR using 1D and 2D 1H-13C HSQC experiments, with a final purity of
>90 %. In instances demanding even higher purity, the Kdo 2 -Lipid A samples were
subjected to hydrophobic interaction chromatography (HIC) using a column packed with
octyl-Sepharose CL-4B (Sigma Aldrich). Samples were eluted using a linear gradient
from of n-propanol in 0.1M ammonium acetate, pH 4.7 (131). Confirmation of the
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identity and purity of Kdo 2 -Lipid A was achieved by collecting a one dimensional 1H-13C
HSQC spectrum in the mixed deuterated solvent mixture, CD 3 OD:CDCl 3 :D 2 O (3:2:1
v/v), which was compared to the published spectrum and assignments in Qureshi et al.
(41). Experiments were performed at 25 ºC on either a cold probe equipped Varian
VNMRS 600 MHz spectrometer or a Varian VNMRS 500 MHz equipped with a Varian
OneNMR™ probe.
2.2.6 PREPARATION OF Kdo 2 -LIPID A AND LIPOTEICHOIC ACID
STRUCTURAL VARIANTS
LIPID A
Production of lipid A from Kdo 2 -Lipid A was accomplished by addition of 1%
acetic acid to the sample and incubation at 70 ºC for 2 hours (132). The sample was then
diluted with endotoxin-free water and centrifuged at 14,000 rpm to pellet the lipid A. The
pelleted lipid A was resuspended in endotoxin-free water aided by sonication; this
process was repeated five times. This sample was then resuspended in a three solvent
mixture of CH 3 OH:CHCl 3 :H 2 O (3:2:1 v/v); the lipid A micelle is soluble in this solvent,
where as any residual Kdo 2 units or trace salts are not. The lipid A in the three solvent
mixture was centrifuged for 20 minutes at 14,000 rpm to pellet any remaining impurities.
The supernatant containing the lipid A was saved, and evaporated to dryness. The dried
sample was then resuspended, with the aid of sonication, in 2 ml of endotoxin-free water,
and loaded onto a NAP-25 column (GE Healthcare). The column was washed with 2 ml
of endotoxin-free water and the pure lipid A was eluted with an additional 3.5 ml of
endotoxin-free water, per the manufacturer’s recommendations.

45

MONOPHOSPHORYL LIPID A
Monophosphoryl lipid A was obtained by hydrolysis of pure lipid A with 0.1 M
HCl at 100 ºC for 45 min (123). The reaction solution was neutralized with 1M NaOH,
and the cleaved 1-phosphate group was washed away from the lipid A by repeated
washing/centrifugation steps. The three solvent mixture CH 3 OH:CHCl 3 :H 2 O (3:2:1 v/v)
was used for the final wash as described above for lipid A.
DEPHOSPHORYLATED Kdo 2 -LIPID A
Dephosphorylated Kdo 2 -Lipid A was prepared from Kdo 2 -Lipid A by acid
hydrolysis with 48 % aqueous HF for 72 hours at 4 ºC with continuous stirring. The HF
was neutralized using saturated sodium bicarbonate. The neutralized solution was then
centrifuged at 35,000 rpm for 25 minutes, and resuspended in endotoxin-free water; this
step was repeated 5-8 times. The final washed sample was then resuspended in a three
solvent mixture of CH 3 OH:CHCl 3 :H 2 O (3:2:1 v/v), and centrifuged and evaporated as
described above for lipid A.
DE-O-ACYLATED Kdo 2 -LIPID A
De-O-acylated Kdo 2 -Lipid A was prepared by overnight incubation in 0.25 N
NaOH at 37 ºC. After centrifuging at 10,000 rpm for 20 minutes to clarify the solution,
the supernatant was saved and the pH adjusted to 3.5 with the addition of 4 M HCl. The
de-O-acylated Kdo 2 -Lipid A was precipitated from the acidified supernatant by addition
of 5 volumes of chilled isobutanol, and then allowed to stand for 12 hours at -20 ºC. The
resulting precipitate was recovered by centrifugation and washed twice with the chilled
alcohol. The precipitate was washed with ice-cold ether-acetone (1:1), and the solvents
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were removed by evaporation under a stream of nitrogen gas (123).
LIPID IVa
Lipid IVa was produced using the E. coli mutant CMR300, which was grown as
described earlier for the mutant strain WBB06. The Lipid IVa was extracted by resuspension

of

the

cell

pellet

in

a

single-phase

Bligh/Dyer

solution

(chloroform:methanol:PBS, 1:2:0.8 v/v), which was stirred for 1 hour at room
temperature. The single-phase supernatant was then converted to an acidic two-phase
Bligh/Dyer (chloroform:methanol:0.1N HCl, 2:2:1.8 v/v) solution by addition of the
proper volumes of chloroform and water. The two-phase solution was centrifuged and
the lower phase saved and evaporated under nitrogen gas. The dried lower phase was
then re-suspended in 5 ml of chloroform/methanol/water (2:3:1, v/v), and applied to a 2
ml DEAE cellulose column (acetate form) equilibrated with the same solvent mixture.
The column was washed with 20 column volumes of chloroform/methanol/water (2:3:1,
v/v).

The

Lipid

IVa

chloroform/methanol/aqueous

was

eluted

ammonium

with
acetate

successive
(2:3:1,

10

ml

v/v),

with

steps

of

increasing

ammonium acetate concentrations of 60, 120, 240, and 480 mM (133). The fractions of
the 240 and 480 mM eluates were checked by NMR for the presence of Lipid IVa. The
Lipid IVa was detected in the 480 mM ammonium acetate fractions, and in the last 240
mM fraction.
All structural variants were analyzed for identity and purity by NMR
spectroscopy using one and/or two dimensional 1H-13C HSQC experiments using the
three solvent system with deuterated solvents CD 3 OD:CDCl 3 :D 2 O) (3:2:1 v/v). All
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experiments were carried out at 25 ºC on either a cold probe equipped Varian VNMRS
600 MHz spectrometer or a Varian VNMRS 500 MHz equipped with a Varian
OneNMR™ probe.

2.3 RESULTS AND DISCUSSION
2.3.1 EXPRESSION, PURIFICATION, CHARACTERIZATION, AND
ISOTOPIC LABELING OF SOLUBLE CD14 IN Pichia pastoris
Considerable enhancement of Pichia expression levels was achieved by
significant modification and optimization of the parameters for the transformation of the
sCD14 construct into Pichia. Additional optimization of the screening process to identify
clones with the highest protein expression levels led to more efficient identification of
colonies with high expression levels. Furthermore, altering the composition of the
standard culture medium, and fine-tuning of the methanol levels in the cultures led to a
significant enhancement of protein expression. The final transformation, screening, and
expression methods we developed have evolved far beyond the standard protocols and
optimizations suggested by the supplier, Invitrogen (Carlsbad, CA). Additionally, a
robust fermentation protocol for expression was developed yielding large quantities of
unlabeled sCD14. Secretion of sCD14 into the expression medium was accomplished via
the α-factor secretion signal contained in the pPICZαA expression vector from
Invitrogen (Carlsbad, CA), and in conjunction with a 6x Histidine tag on the C-terminus
greatly simplified purification (Figure 2.2).
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Figure 2.2: Schematic for cloning of soluble CD14 into the pPICZαA vector.
Schematic for cloning of sCD14 sequence (residues 20–171) in pPICZαA vector along with a
6x His-tag for expression in Pichia pastoris. Recombinant sCD14 is secreted into the
extracellular medium by the yeast α-factor secretion signal via cleavage at the Kex2 protease
site.
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Immobilized metal-affinity chromatography (IMAC) was employed to recover sCD14
from the expression media and yielded a partially pure product. The concentrated eluate
from the IMAC column was then subjected to size-exclusion chromatography yielding a
single band with an approximate molecular weight of ~32 kDa as shown by SDS-PAGE
gel analysis (Figure 2.3). The observed ~32 kDa molecular weight is higher than the
calculated molecular weight of ~18 kDa, which is likely due to the presence of
glycosylation at the two potential N-glycosylation sites, Asn18 and Asn132, contained in
the sCD14 152 residue truncation (74). Deglycosylation studies using the enzyme
PNGase F (New England BioLabs), which cleaves N-linked glycosylations, resulted in
the disappearance of the 32 kDa band and appearance of a single band at ~20 kDa
(Figure 2.4), supporting the presence of N-linked glycosylations.
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Figure 2.3: SDS-PAGE and Western Blot analysis of soluble CD14 expressed in
Pichia pastoris.
(SDS-PAGE) Coomassie stained SDS-PAGE showing a single band for sCD14. (WB)
Western blot of sCD14 with the monoclonal CD14 antibody, Mem-18, confirming the band’s
identity.
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The identity of the purified sCD14 was confirmed via western blot using the monoclonal
antibody MEM-18 (Abcam), which binds within the endotoxin-binding domain of CD14
(Figure 2.3) (110, 134). N-terminal sequencing (Dana-Farber Cancer Institute) provided
additional confirmation that the purified protein was CD14.
Proper folding of the Pichia expressed sCD14 was confirmed through circular
dichroism spectroscopy (Figure 2.5). The circular dichroism (CD) spectra of our Pichia
produced 152-residue CD14 truncation matched that of CD spectra collected on the 152residue truncation by previous groups (135). The biological activity of the sCD14 was
confirmed using a cell-based assay utilizing THP-1 human monocyte cells. THP-1 cells
naturally express human TLRs 1-10 but not CD14.
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Figure 2.4: SDS-PAGE of soluble CD14 expressed in Pichia pastoris
deglycosylated by PNGase F.
SDS-PAGE of pure sCD14 (1) and deglycosylated sCD14 (2) after cleavage of N-linked
glycosylations by PNGase F. Sample shows some residual glycosylated sCD14 present, likely
due to inadequate incubation time, while the majority was deglycosylated. The low molecular
weight streak is cleaved glycosyl chains.

Figure 2.5: Far-UV Circular Dichroism spectra of soluble CD14.
Circular dichroism spectra is the average of five scan collected on a 1μM sCD14 sample in
PBS buffer, pH 7.4 at 25ºC.
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The absence of endogenous CD14 allows the biological activity of our recombinant
sCD14 to be monitored by its ability to up-regulate production of the inflammatory
mediator NF-kB. This assay was performed using THP1-Blue cells (Invivogen, San
Diego, CA) containing a stably transfected NF-κB-inducible reporter, secreted embryonic
alkaline phosphatase (SEAP), whose levels can be quantitatively measured using the
QUANTI-Blue colorimetric reagent (Invivogen). The THP1-Blue cells were incubated
singly or in varying combinations with sCD14, recombinant human LBP (R&D Systems,
Minneapolis, MN), recombinant human CD14 (R&D Systems), E.coli K-12 full-length
LPS

(Invivogen),

Kdo 2 -Lipid

A,

dephosphorylated

Kdo 2 -Lipid

A,

lipid

A,

monophosphoryl lipid A, or LTA. Up-regulation of the THP-1 cell’s production of NFκB, is indicative of an up-regulation of the inflammatory response by sCD14. The level
of NF- κB was quantified via detection of SEAP. An upsurge in NF-κB induces
expression of the NF-κB-regulated inflammatory cytokines, such as IL-1, IL-6, and IL-8
which are associated with increased activation of the inflammatory response (136). The
sCD14 was found to be biologically functional in this assay, as it was able to up-regulate
the production levels of NF-κB over that of cells incubated without CD14 (Figure 2.6).
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Figure 2.6: Biological activity analysis of soluble CD14 with endotoxin ligands.
Responses of THP1-blue cells-mediated by full-length wild-type sCD14 (8nM) and pure
Pichia pastoris produced sCD14 (8nM). Upon stimulation with ~1μM of one of five agonist,
E. coli K-12 full-length LPS, B. subtilis LTA, Kdo 2 -Lipid A, Lipid A, the partial agonist
monophosphoryl Lipid A, or the non-binder dephosphorylated-Kdo 2 -Lipid A stimulation was
assessed by measuring the levels of NF-κB, which was quantified by its induction of the
reporter secreted embryonic alkaline phosphatase (SEAP). SEAP levels were detected via
absorbance readings at 630 nm of culture supernatants in SEAP detection medium. Control
experiments are the responses generated by rhCD14 and sCD14 alone. The values shown
represent an average of three separate measurements. Error bars represent average standard
deviation across all three experiments.
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The sCD14 produced in this work using P. pastoris showed essentially the same level of
NF-κB up-regulation as the rhCD14 (R&D Systems), which was produced using Chinese
hamster ovary (CHO) cells. The NF-κB levels induced by sCD14 were substantially
higher than the background levels generated through the endogenous NF-κB response of
the THP-1 cells, demonstrating that our sCD14 is capable of up-regulating production of
NF-κB in human monocytes. Results from these experiments demonstrate that the sCD14
produced using Pichia pastoris is capable of binding a variety of endotoxins, and
initiating the increased production of NF- κB, which is indicative of biological activity.
Additionally, the Pichia expression system allowed us to produce uniformly labeled
sCD14 samples for use in NMR studies.
Other groups have previously reported the expression and purification of
recombinant sCD14 from P. pastoris (135, 137). However, production of endotoxin-free,
isotopically labeled sCD14 for use in NMR investigations was not demonstrated in their
studies. For the first time, isotopic labeling of sCD14 was carried out using

15

N

ammonium sulfate and 13C methanol to produce both single and double labeled versions
of sCD14, as evidenced from the 1H-15N HSQC spectra of sCD14 (Figure 2.7).
Approximately half of the 152-residues in sCD14 are clearly visible in the 1H-15N HSQC
spectrum of sCD14. The high degree of spectral overlap in the 1H-15N HSQC spectrum is
primarily due to the high number of aliphatic amino acids present in sCD14, ~42% of the
total amino acid content. These overlapping resonances form broad multiplets, which
impede accurate identification/ determination of the total number of residues visible.
Some of the missing peaks could be due to deprotonations in the pH 8.9 buffer. Other
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missing peaks might be a result of exchange broadening lowering the intensity levels
below the threshold of detection. Additionally, the truncated sCD14 sequence contains 12
prolines, which do not produce a signal 1H-15N HSQC spectra.

57

Figure 2.7: 1H-15N HSQC of isotopically labeled soluble CD14 expressed in Pichia
pastoris.
15

N-labeled sCD14 N-terminal 152-residue truncation in PBS buffer, pH 8.9, containing 2M
D 5 -glycine collected at 37 ºC.
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2.3.2 EXPRESSION, PURIFICATION, CHARACTERIZATION, AND
ISOTOPIC LABELING OF Kdo 2 -LIPID A AND LIPOTEICHOIC ACID
An extensive panel of LPS- and LTA-based ligands with varying partial structures
corresponding to agonists, partial agonists, antagonists, and non-binders has been
generated in

13

C,

15

N isotopically labeled forms. Successful production and purification

of Kdo 2 -Lipid A has been accomplished through growth of E. coli WBB06 in minimal
medium, and labeled samples were produced by supplementing the media with
glucose and

13

C6-

15

N ammonium chloride. Purification of Kdo 2 -Lipid A directly from cell

membranes was achieved using a multi-step process resulting in pure hexaacylated Kdo 2 Lipid A samples, and removing any residual traces of undesired underacylated forms and
contaminating lipoproteins and peptides. Lipid IVa was produced by growth of E. coli
mutant CMR300 in minimal media, and labeling was accomplished in the same manner
as described for E. coli mutant WBB06.
The resulting samples were of high-purity and produced in milligram quantities in
both unlabeled and labeled versions, as shown by the 1H-13C HSQC of Lipid A (Figure
2.8).
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Figure 2.8: 1H-13C HSQC spectrum of 13C isotopically labeled Lipid A.

The two-dimensional 1H-13C HSQC spectrum of isotopically labeled Lipid A in
CDCl 3 :CD 3 OD:D 2 O (2:3:1, v/v) mixed solvent system showing correlations within the sugar
headgroup and acyl chain regions.
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Additionally, the Kdo 2 -Lipid A and lipid A structural variants were also produced
in pure milligram quantities in both labeled and unlabeled forms. Since the overall lipid
A-like character is maintained in these partial structures, it is likely that they bind to a
similar region on CD14. The specific structural interactions of individual features and
motifs can be distinguished from the fully intact agonist ligands. The ability of the
agonistic ligands to elicit an immune response was confirmed through the THP-1 human
monocyte cell based assay (Figure 2.6). These highly purified, well characterized ligands
serve as aids in the dissection of the sCD14 binding interactions, revealing the features
necessary for recognition and binding by CD14 as described in Chapter 4. . Not all Kdo 2 Lipid A and lipid A variants we prepared were used in NMR binding studies. The
structural variants, Kdo 2 -Lipid A, lipid A, dephosphorylated Kdo 2 -Lipid A, and
monophosphoryl lipid A were used in the THP-1 cell based assay and for NMR studies.
Lipid IVa was also use in NMR binding studies. The only variant not used in either a cell
based assays or for NMR studies was de-O-acylated Kdo 2 -Lipid A, which was the most
difficult to produce. However, the high-quality NMR data collected using the other
structural variants did not require the use of de-O-acylated Kdo 2 -Lipid A for structural
information
The gram-positive endotoxin LTA was produced and extracted from Bacillus
subtilis ATCC 6633™ using n-butanol in order to prevent the structural decomposition
associated with traditional phenol extraction methods (50). We were able to successfully
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produce milligram quantities of 13C, 15N labeled LTA ligands as demonstrated by the 1H13

C HSQC spectra of LTA (Figure 2.9). The effects of CD14 binding of the

13

C-

isotopially labeled LTA lipid anchor is described in Chapter 5.
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Figure 2.9: 1H-13C HSQC spectrum of
Lipoteichoic acid.

13

C isotopically labeled full-length

Partially annotated two-dimensional 1H-13C HSQC spectrum of 13C isotopically
labeled LTA from B. subtilis in PBS buffer pH 8.9 containing 2M D 5 -glycine.

63

CHAPTER 3. SOLUTION NMR STUDIES PROVIDE A
STRUCTURAL BASIS FOR ENDOTOXIN PATTERN
RECOGNITION BY THE INNATE IMMUNE RECEPTOR CD14
This chapter is a modified version of a paper first published in Biochemical and
Biophysical Research Communications in 2008:
“Reprinted from Biochemical and Biophysical Research Communications, Vol. 368,
Albright, S., Chen, B., Holbrook, K., and Jain, N. U., Solution NMR studies provide
structural basis for endotoxin pattern recognition by the innate immune receptor CD14,
231-237, (2008), with permission from Elsevier.”
As first author, I performed a majority of the experimental work and sample preparations.
Nitin Jain carried out the NMR spectroscopy experiments, processed, and analyzed the
NMR data. Bin Chen, and Kristen Holbrook assisted in the Pichia pastoris growth and
purifications of CD14.

3.1 INTRODUCTION
To date, several studies have confirmed interactions of CD14 with a variety of
microbial ligands such as lipopolysaccharide (LPS) from gram-negative bacteria,
lipoteichoic acid (LTA), and peptidoglycan (PGN) from gram-positive bacteria,
lipoproteins, lipoarabinomannan, polymannuronic acids, and even synthetic molecules
(17, 57, 97, 138-140). The ability of CD14 to interact with such structurally diverse
endotoxins has led to the hypothesis that CD14 functions as a pattern recognition receptor
by recognizing and binding to different pathogen-associated molecular patterns (17). It is
believed that this pattern recognition may be important for the high selectivity of CD14mediated cellular activation, and the distinctiveness of the signaling pathway in response
to specific ligands (141). However, the mode of recognition of these structurally distinct
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patterns by CD14 is not clear, since structural details for CD14 in complex with any of its
ligands is not available. Deletion mutagenesis experiments and epitope mapping with
monoclonal antibodies and proteases have previously identified several broad regions
(residues 39–44, 57–64, 81– 100) on CD14 that are crucial for the binding of various
microbial ligands and possess overlapping sites of interaction for these ligands (93, 109111, 138). More recently, the high-resolution X-ray crystal structure for mouse sCD14
without any ligand has been determined (75), in which a potential endotoxin binding
pocket can be seen at the N-terminus. Clustered around this pocket are the binding
regions identified previously from the mutagenesis experiments. However, apart from
these general interpretations, no direct structural evidence for differential binding to
specific residues of CD14 is available.
In order to confirm the role of CD14 as a pattern recognition receptor, and
provide a structural basis for endotoxin recognition and binding by CD14, direct
structural evidence is critical. In order to determine the potential contribution of CD14
residues to endotoxin pattern recognition, we have analyzed the binding of various
endotoxin ligands to CD14 at a molecular level using solution NMR spectroscopy. NMR
spectral changes were mapped out for the binding interactions between the residues of a
fully functional 152-residue N-terminal domain of CD14 and the cell-wall components
from gram-negative and gram-positive bacteria. The CD14 was expressed and
isotopically labeled in Pichia pastoris. The gram-negative and gram-positive cell wall
components differ from one another both structurally and with respect to their ability to
stimulate innate host responses via CD14. Comparison of the pattern of residues in CD14
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affected upon binding of each ligand reveals differential changes in the NMR spectra of
CD14 for each ligand. However, the pattern of residues affected by binding of these
ligands utilizes both a similar set of residues as well as a subset of different residues
specific to the ligand bound. This provides, for the first time, direct structural evidence
for endotoxin specific differential recognition by CD14 and supports the pattern
recognition hypothesis. Another interesting finding from the observed spectral changes is
that the mode of binding may be dynamically modulated, which may provide a
mechanism for pattern recognition.

3.2 MATERIALS AND METHODS
3.2.1 EXPRESSION AND PURIFICATION OF ISOTOPICALLY LABELED
RECOMBINANT SOLUBLE CD14 IN Pichia pastoris
As described in detail in the preceding chapter, the gene sequence encoding the
N-terminal endotoxin-binding domain of human sCD14, consisting of 152 residues after
the signal peptide sequence (20–171), was codon-optimized for expression in yeast, and
was cloned into the pPICZαA vector (Invitrogen) by BIO S&T (Montreal, Canada). The
sCD14 pPICZαA construct was transformed into wild-type X-33 P. pastoris cells, and
the individual colonies were screened using small-scale cultures to select the best sCD14expressing clone. Expression levels were determined by SDS–PAGE analysis of secreted
sCD14 protein in the medium.
At the time of original publication, the protocol used for large-scale shake flask
expression of sCD14 was as follows. In a 2.8 liter baffled shake flask, 1 liter of BMD
medium (Invitrogen) was inoculated with the best expressing colony and grown for ~24
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hrs to an OD 600 of ~12. The culture was then spun down and the cells resuspended in 250
ml of BMMY medium (Invitrogen). The yeast extract and peptone used in the BMMY
medium was filtered through acrodisc mustang E filters (Pall) to reduce the endotoxin
levels in the media. Isotopic labeling was accomplished by substituting the primary
nitrogen source ammonium sulfate with

15

N labeled ammonium chloride. Protein

expression was carried out for 4 days with addition of methanol everyday at 0.5 % of the
culture volume. At the end of the expression period the cells were spun down, and the
sCD14 was purified from the supernatant using a column containing Talon cobalt metalaffinity resin (Clontech). The column was washed with 20 column volumes of PBS buffer
(pH 7.4), and washed with 1 column volume of PBS containing 20 mM imidazole, and
the bound CD14 eluted with PBS containing 200 mM imidazole.
The protein eluted from the IMAC column was further purified by size exclusion
chromatography using a HiPrep Sephacryl S-100 column (GE Healthcare) equilibrated
with PBS. Pure endotoxin-free fractions of sCD14 were pooled, concentrated, and used
for characterization via SDS–PAGE and Western blot analysis. Samples of sCD14 (~1
µg) were loaded, in duplicate, on Novex 18 % tris–glycine gels (Invitrogen) and run
following the manufacturer’s recommendations. One half of the gel was then coomassieblue stained and de-stained overnight, while the other half of the gel was transferred onto
a PVDF membrane (Pierce) for Western blot analysis. The membrane was incubated with
the monoclonal antibody for CD14, MEM-18, and developed using metal-enhanced DAB
(Pierce) per manufacturer’s directions (see western blotting protocol in the Appendix).
Circular dichroism (CD) spectra in the far-UV region (190–250 nm) were
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collected for 10µM samples of sCD14 at 25 ºC in PBS buffer, pH 7.4, on an AVIV
Model 202 spectrometer with and without endotoxins. The circular dichroism spectrum
were displayed by calculating the molar ellipticity values and plotted against the
wavelength.
3.2.2 BIOLOGICAL ACTIVITY ASSAYS ON RECOMBINANT SOLUBLE
CD14-ENDOTOXIN BINDING DOMAIN
For the activity assay, THP1-Blue cells (Invivogen) stably transfected with an
NF-κB-inducible reporter, secreted embryonic alkaline phosphatase (SEAP), were
cultured in supplemented RPMI 1640 medium at 37 ºC in a 5 % CO 2 environment. Cells
were spun down and resuspended at 1x106 cells/ml in fresh growth media. 100 µl of cell
suspension was added to each well of a 96-well plate along with sCD14 or recombinant
human CD14 (rhCD14) (R&D Systems), recombinant human LBP (rhLBP) (R&D
Systems), and one of three individual ligands. The three ligands used were ReLPS (List
Biological Laboratories), S. aureus LTA (Invivogen), or the peptidoglycan derivative
MDP (Sigma Aldrich). The ligands or proteins alone served as positive controls with
endotoxin-free water and growth media as negative controls. After incubation for 20–24
hours at 37 ºC under 5 % CO 2 , the 96-well plate was spun down, and 10 µl of supernatant
from each well was added to 200 µl of Quanti-Blue reagent (Invivogen) in a new 96-well
plate to quantitate the amount of SEAP present. This plate was then incubated at 37 ºC,
and readings at 630 nm were made every hour for 6 hours using a Biotek Synergy2 plate
reader. A final reading of the plate was taken after 18–20 hours.
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3.2.3 NMR STUDIES OF SOLUBLE CD14 — ENDOTOXIN INTERACTIONS
CD14 protein samples for the NMR experiments were prepared in PBS buffer pH
7.4 with typical protein concentrations of ~0.2 mM. Stock solutions of endotoxin ligand
compounds, ReLPS, a rough strain form of LPS from Salmonella minnesota Re595 (List
Biological Laboratories), LTA from Staphylococus aureus (Invivogen), and MDP
(Sigma–Aldrich) were prepared at a 5 mg/ml concentration in D 2 O to ensure minimal
dilution of protein upon addition of the ligand. The endotoxin stock solutions were
extensively sonicated to ensure complete solubilization of the ligands. NMR samples of
protein:ligand were prepared in a molar ratio of 1:1, except for MDP, where a ratio of
1:10 was used. Also present in each sample was rhLBP at a concentration of 5μM.
Protein:ligand samples were incubated for 30 minutes at 37 ºC to ensure complete
binding of ligand (142). Sensitivity-enhanced 1H–15N HSQC spectra (143) were recorded
for each sample with and without the ligand. Data was collected with 1024 complex
points in the direct dimension and 128 complex points in the indirect dimension. All
NMR experiments were carried out on a Varian VNMRS 600 MHz spectrometer at 17 ºC
equipped with a cold probe. NMR data was processed and analyzed with the Felix
software package (Molecular Simulations).

3.3 RESULTS AND DISCUSSION
3.3.1 EXPRESSION AND ISOTOPIC LABELING OF SOLUBLE CD14 IN
Pichia pastoris
We were able to accomplish 15N isotopic labeling in P. pastoris in an inexpensive
manner using 15N ammonium chloride as the nitrogen source. This allowed us to produce
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milligram quantities of uniformly

15

N labeled samples of the fully functional sCD14

fragment, which includes the region for endotoxin binding (70). Both the SDS-PAGE and
Western blot indicate that the protein is expressed as a single isoform and in an
endotoxin-free form, which is quite valuable for high-resolution NMR structural studies
(Figure 2.3).
In order to evaluate whether the purified protein was correctly folded, Circular
Dichroism (CD) spectroscopy was used to study the solution secondary structure of
sCD14. The far-UV CD spectrum of purified sCD14 is shown in Figure 3.1. As seen
from the CD spectrum, sCD14 contains a mixture of α-helical and β-sheet type
structures. This is confirmed by a recent X-ray structure of mouse sCD14, which depicts
an α/β-fold for the protein (75). The spectrum of sCD14 changes minimally upon
addition of the endotoxin ligand ReLPS, a close structural relative of Kdo 2 -Lipid A
produced by Salmonella minnesota Re959. The lack of significant changes in the CD
spectrum suggests that there are no global conformational changes in the protein upon
ligand binding (108).
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Figure 3.1: Far-UV circular dichrosim spectra of soluble CD14 with and without
ReLPS.
sCD14 (blue line) and ReLPS complexed sCD14 (red line). Both spectra are average of five
scans.
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3.3.2 DETERMINATION OF BIOLOGICAL ACTIVITY OF SOLUBLE CD14
To test the biological activity of sCD14 a cell-based assay was used. The ability
of sCD14 to enhance the NF-κB-induced cytokine production from various endotoxin
ligands, such as ReLPS, S. aureus LTA, and the PGN-derived MDP was monitored. This
assay relies on detection of the NF-κB-induced reporter, SEAP, upon activation of an
established cell line such as THP1-Blue by endotoxins in presence of CD14 (Figure 3.2).
Compared to the activation of THP1-Blue cells by the protein or ligands alone, addition
of ReLPS to sCD14 and rhLBP produced an almost 3-fold increase in production of NFκB, while LTA showed an almost 5-fold increase. This is consistent with the observation
that LPS and LTA are highly potent activators in mammals. On the other hand, PGNderived ligand, MDP, showed only a small activation compared to protein or ligand
alone. It has been reported previously that sCD14 shows low levels of cellular
responsiveness to MDP and only at saturating concentrations (97).
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Figure 3.2 Biological activity analysis of soluble CD14 with endotoxin ligands.
Responses of THP1-blue cells-mediated by full-length wild-type sCD14 (rhCD14, 400 ng/ml)
and purified sCD14 (sCD14, 200 ng/ml) upon stimulation with three endotoxins, ReLPS (1
μg/ml), S. aureus LTA (1 μg/ml), and MDP (200 ng/ml). After 24 hours incubation, endotoxin
stimulation was assessed by measuring the levels of NF-κB inducible reporter alkaline
phosphatase (SEAP) using a SEAP detection medium with absorbance values at 630 nm.
Control experiments in form of responses to rhCD14 and gCD14 alone are shown as well. The
values shown represent an average of three separate measurements and the error bars show the
range.
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However, another possibility that cannot be ruled out is that this small activation is not
due to MDP, but due to contamination of this commercial MDP sample with minute
traces of LTA and/or lipopeptides. Commercial PGN samples are commonly known to
suffer from contamination by residual cell wall components such as teichoic acids,
lipopeptides, lipoproteins, and lipoteichoic acid (144). Because MDP is derived from
PGN, it is entirely possible that it too suffers some level of residual contamination. This
is illustrated by the extensive purification techniques applied to PGN in order to obtain
pure MDP samples to test the binding and activation of another intracellular immune
receptor (145). In these circumstances, the multi-step acid hydrolysis needed to produce
MDP from PGN should have significantly reduced the residual level of contamination.
Based on the similar levels of NF-κB response observed for each ligand in the
presence of sCD14 and rhCD14, it can be inferred that both possess similar abilities to
induce NF-κB release by human monocytes (102). Therefore, results from these
experiments indicate that our recombinant soluble CD14 can bind and induce cellular
effects in response to different endotoxins similar to wild-type protein, confirming its
biological activity.
3.3.3 CHANGES IN NMR SPECTRA OF CD14 UPON ENDOTOXIN BINDING
PROVIDES STRUCTURAL EVIDENCE FOR PATTERN RECOGNITION
In order to gain a structural perspective regarding the mechanism by which CD14
is able to recognize and differentially bind a diverse array of endotoxin patterns through a
common binding site(s), we have investigated the interaction of the endotoxins ReLPS,
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LTA, and MDP using 1H–15N HSQC NMR spectroscopy. The endotoxin ligands ReLPS
and LTA represent the primary endotoxins of gram-negative and gram-positive bacteria,
and are potent activators of the inflammatory response in mammals. MDP is the minimal
PGN structure observed in past studies necessary for adjuvant activity (97). For many
years PGN was thought to be the gram-positive endotoxin. However, it has only been in
the last few years that PGN and its derivatives have been excluded as the gram-negative
endotoxin. As mentioned above, the immunostimulatory effects attributed to MDP and
PGN are likely due to trace contamination of the samples with other gram-positive cell
wall components, such as LTA. In the NMR binding studies performed using 15N-labeled
CD14, we chose to include the PGN-derivative ligand, MDP, in order to evaluate
structurally whether binding by CD14 could be occuring.
The binding studies described here constitute the first molecular level NMR
characterization of structural interactions between an innate immune system receptor and
endotoxins. Analysis of NMR spectra with and without the endotoxin ligands reveals no
drastic overall change in the protein’s HSQC spectra. This is in line with the circular
dichroism analysis, which also showed no major global structural changes. However, a
number of CD14’s 1H and

15

N backbone amide peaks show specific changes in their

resonances with the addition of each ligand, possibly from local structural changes. Both
line-broadening and chemical shift changes are observed in the spectra with ReLPS and
LTA, but in the case of MDP, only minor chemical shift perturbations can be seen. A
comparison of selected regions in the HSQC spectra exhibiting the largest changes upon
ligand addition is shown in Figure 3.3 A–D. The most striking characteristic observed in
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these regions is the pattern of sCD14 resonances affected by each ligand. It is evident
from the spectra that ReLPS and LTA affect similar resonances in the CD14 spectra.
However, the identity of resonances affected by individual ligands differs. For example,
ReLPS and LTA both affect peaks ‘‘c” and ‘‘h” in the spectra, with all three ligands
affecting peak ‘‘c”. However, peaks ‘‘e” and ‘‘f” are affected only by ReLPS, while LTA
affects only peaks ‘‘b” and ‘‘g” in the regions shown. It is worth noting that the minor
changes seen in the spectra of MDP and CD14 appear quite similar to that of LTA bound
sCD14 (Figure 3.3 C & D). While this could be due to sCD14 binding MDP, we believe
this indicates that MDP is not being bound by CD14. The similarity between the changes
seen in the MDP spectra and the changes in the bound LTA spectra could be an
indication that traces of some gram-positive cell wall component(s) remained as a trace
impurity in the MDP sample (144). In addition, it has now been shown that sCD14 does
not bind any low molecular weight PGN fragments such as MDP (97, 146, 147).
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Figure 3.3: Changes upon endotoxin addition to the 1H-15N HSQC spectra of soluble
CD14.
Comparison of changes upon endotoxin ligand addition for a representative set of resonances in
the 600 MHz 1H-15N HSQC spectra of 15N labeled sCD14 in PBS pH 7.4. (A) sCD14 only, (B)
sCD14 in 1:1 complex with ReLPS, (C) sCD14 in 1:1 complex with LTA and (D) sCD14 in 1:10
complex with MDP.
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Our observation of the ability of specific residues to differentially affect
endotoxin binding demonstrates previously unobserved residue level binding
characteristics for CD14 and provides a structural basis for pattern recognition. It is
possible that each endotoxin may, either directly or indirectly, individually affect
different sets of residues. The set of individual residues affected upon binding of a ligand
may depend on the characteristic molecular pattern possessed by the ligand. Given
CD14’s broad ligand specificity, several of the structural features affected in CD14 are
likely shared between the different endotoxins in order to maintain spatial and functional
similarity within the interaction site. Because assignments for CD14 are not currently
available, it is not possible to locate the exact regions affected by ligand binding in the
sequence of CD14. However, it is probable that the affected regions shown are the
binding sites of the ligands, as the chemical shift perturbations and broadening seen upon
binding of ReLPS or LTA are much smaller in other regions of the sCD14 spectra.
However, at this stage, spectral changes caused by conformational changes in other
regions of the protein due to ligand binding cannot be ruled out. Regardless of whether
the spectral changes are a result of direct binding interactions or are caused indirectly, it
is clear that recognition of endotoxin ligands depends on specific contributions of select
CD14 residues. The use of specific groups of residue may have implications for pattern
recognition.
Another significant feature observed in the NMR spectra of CD14, particularly
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when either ReLPS or LTA were bound, is that in a number of cases the resonances
affected by binding split into multiple peaks (Figure 3.4). We interpret this splitting as a
result of changes in the dynamics of CD14’s flexible regions from fast to slow exchange
on the NMR chemical shift time scale.
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Figure 3.4: 1H-15N HSQC spectrum of exchange rate changes in ReLPS bound
soluble CD14
Splitting of a representative resonance in sCD14 in PBS pH 7.4 (left sub-spectrum) into
multiple peaks upon complexation with ReLPS (right sub-spectrum), indicating change in
dynamics to slower exchange on the NMR time scale.
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This signifies that various conformational sub-states can be occupied, from within a
dynamic ensemble of interconverting populations, in order to specifically select for
binding. Interestingly, based on the crystal structure of mouse sCD14, the regions
previously identified as acting in endotoxin binding map to a highly flexible hydrophilic
rim and also the bottom of the large hydrophobic pocket (75). In the CD14 crystal
structure, the hydrophobic pocket is fairly rigid, while the residues on the hydrophilic rim
exhibit multiple conformations in addition to having high average temperature factors. In
addition, the electron density for this region is rather poorly defined in the crystal
structure. Based on these observations, we conclude that the flexibility of the hydrophilic
rim allows it to interact with structurally diverse sugar moieties. At the same time, the
rigid but large nature of the hydrophobic pocket would allow it to accommodate ligands
with structural variations in the hydrophobic portion, such as LPS and LTA. Therefore,
we propose that the structural characteristics of CD14’s binding site help impart its broad
specificity in ligand recognition, through the use of specific residue combinations. The
dynamic modulation of CD14 may also play an important role in providing a mechanism
by which structurally diverse endotoxin ligands can be bound in a common binding site.
The NMR observed structural and dynamic changes presented here lend credence to this
possibility.
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CHAPTER 4. NMR SPECTRAL MAPPING OF THE LIPID A
MOLECULAR PATTERNS AFFECTED BY INTERACTION
WITH THE INNATE IMMUNE RECEPTOR CD14
This chapter is a modified version of a paper first published in Biochemical and
Biophysical Research Communications in 2009:
“Reprinted from Biochemical and Biophysical Research Communications, Vol. 378,
Albright, S., Agrawal, P., and Jain, N. U., NMR spectral mapping of lipid A molecular
patterns affected by interaction with the innate immune receptor CD14, 721-726, (2009),
with permission from Elsevier.”
As first author, I performed a majority of the experimental work and produced all of the
samples used. I also carried out some of the NMR spectroscopy. Prashansa Agrawal
aided in the processing and analysis of NMR spectra, and I assisted her in making the
heteronuclear assignments for Kdo2-Lipid A. Nitin Jain performed a number of the NMR
experiments, and was responsible for the final analysis of all NMR data.

4.1 INTRODUCTION
Bacterial endotoxins such as lipopolysaccharide (LPS), which comprises part of
the outer cell-wall of gram-negative bacteria, are potent immunostimulators and causative
agents for the pathogenesis of gram-negative bacterial sepsis in higher organisms.
Chemically, LPS is composed of a variable polysaccharide region covalently linked to a
conserved phospholipid known as lipid A, the source of biological potency in LPS.
Studies using lipid A, synthetic analogs, as well as preparations of lipid A variants from a
variety of different bacterial strains, have been previously carried out to evaluate the
structural features of lipid A necessary for endotoxic activity (126, 148). Results from
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these studies point to the length and number of acyl chains as well as the phosphorylation
state of the disaccharide backbone to be major contributing factors to lipid A’s
endotoxicity. Additionally, by conformational analysis of lipid A aggregates, it was
deduced that the molecular shape of lipid A and nature of its aggregate structures can be
correlated to the level of endotoxicity (149). An emerging consensus is that the
requirement of particular structural characteristics may be embodied in specific
interactions of lipid A with host cell receptors. In receptors such as LBP, CD14, MD-2,
and TLR4 these interactions may function in modulating the bioactivity of lipid A in the
inflammatory response pathway. Structural studies of lipid A interactions with these
receptors are therefore necessary to understand how they enable cells to respond to lipid
A.
A better understanding of CD14–lipid A interactions could be facilitated through
detailed structural characterization of lipid A in complex with CD14. It is known that
CD14 functions similarly in both its membrane-bound (mCD14) and soluble (sCD14)
forms as a pattern recognition receptor, recognizing various pathogen-associated
molecular patterns (PAMPs) with high affinity (17, 138, 139). This recognition is
accomplished through an endotoxin binding and functional region of CD14 that is
contained in the first N-terminal 152 residues of the molecule (70). A recent crystal
structure of murine sCD14 revealed within this N-terminal region, a large hydrophobic
pocket surrounded by a hydrophilic rim to which endotoxins like lipid A can potentially
bind (75). However, since this crystal structure was solved without a bound ligand,
information regarding the identity of specific lipid A structural motifs involved in
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interacting with CD14 is not available. Such information is crucial to the rational design
of CD14 targeted LPS antagonists.
NMR structural studies of lipid A in complex with CD14 and other host cell
receptors offer a viable option to obtain detailed structural information on their
interactions. However, the lack of availability of isotopically labeled lipid A ligands has
been a limiting factor to undertaking such studies. In the present study, we have
overcome this difficulty by preparing Kdo 2 –Lipid A, a lipid A variant, in a highly pure
13

C, 15N isotopically labeled form. While lipid A is the minimal structural unit needed for

biological activity, addition of a 3-deoxy-D-manno-octulosonic acid disaccharide unit
(Kdo 2 ) to lipid A results in a molecule which sCD14 binds with high, lipid A-like,
affinity. Kdo 2 -Lipid A has the additional benefit of being a chemically well-defined
endotoxin making it quite suitable for solution NMR studies (122). In an effort to
determine the potential contributions of various structural elements of lipid A in its
recognition by CD14, we have performed detailed NMR spectral mapping of isotopically
labeled Kdo 2 –lipid A bound to sCD14. We now report, for the first time, the identity of
structural regions in this agonist ligand strongly affected by complex formation with
sCD14, as well as their differential dynamic behavior. These studies constitute the first
direct structural observations of interactions of an LPS agonist ligand with a host cell
receptor in solution, and provide valuable insights into the mechanism of lipid A pattern
recognition by sCD14.
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4.2 MATERIALS AND METHODS
4.2.1 PREPARATION AND ISOTOPIC LABELING OF Kdo 2 -LIPID A IN
Escherichia coli WBB06
Kdo 2 -Lipid A was prepared from the heptosyltransferase-deficient E. coli mutant
WBB06 (kindly provided by Christian Raetz, Duke University). WBB06 was cultured in
M9 minimal medium at 37 ºC for 22–24 hours. One liter of M9 medium contained 7 g
Na 2 HPO 4 , 3.5 g KH 2 PO 4 , 0.5 g NaCl, 1 mL trace metals solution, 4 g D-glucose, 1 g
NH 4 Cl, and 12 μg/ml tetracycline. For isotopic labeling,

13

C 6 D-glucose and

15

NH 4 Cl

were used in place of their unlabeled versions. Extraction of Kdo 2 -Lipid A from the
harvested cell pellet was performed using a chloroform–methanol mixture, followed by
purification with normal phase and reverse phase column chromatography similar to the
methods of Raetz et al. (122). The center peak fractions from the last chromatography run
were combined and ultracentrifuged for 15 minutes at 256,000g. The final Kdo 2 -Lipid A
product was >90% purity as assessed by thin layer chromatography and matrix-assisted
laser

desorption/ionization

time-of-flight

(MALDI-TOF)

mass

spectroscopy.

Dephosphorylated Kdo 2 -Lipid A was prepared from Kdo 2 -Lipid A by hydrolysis with
48% aqueous hydrofluoric acid for 42 hours at 4 ºC and subsequently purified using
published procedures (150). The loss of the phosphate groups was confirmed by MALDITOF mass spectroscopy analysis.
Induction of NF-κB cytokines in THP1-Blue cells (Invivogen) was performed to
test the biological activity of purified Kdo 2 -Lipid A and dephosphorylated Kdo 2 –lipid A
as described previously (151) and compared to that of ultrapure LPS from Salmonella
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Minnesota strain Re 959 (ReLPS) (List Biological Laboratories), which is structurally
analogous to Kdo 2 -Lipid A. The baseline activation of the cells by the ligands alone was
used as a control experiment.
4.2.2 NMR MEASUREMENTS ON Kdo 2 –LIPID A COMPLEXED WITH
SOLUBLE CD14
Standard two-dimensional (2D) 1H COSY and NOESY spectra were recorded to
obtain proton assignments using a 1 mg/ml sample of unlabeled Kdo 2 -Lipid A in the
deuterated mixed solvent system CDCl 3 :CD 3 OD:D 2 O (2:3:1, v/v) at 17 ºC. Sensitivityenhanced 1H–13C and 1H–15N HSQC experiments were also recorded on a

13

C,

15

N

isotopically labeled sample (1 mg/ml) in the same mixed solvent system to obtain 1H–13C
and 1H–15N correlations, except the D 2 O in the solvent mixture was replaced with H 2 O to
keep the amides protonated in the 1H–15N experiments (143). Chemical shifts were
referenced relative to DSS. Unlabeled samples of a truncated version of full-length
human sCD14 consisting of 152 residues (amino acids 20–171) after the signal peptide
sequence were prepared in Pichia pastoris as described in Chapter 2. The sCD14 samples
used for the NMR experiments were prepared in PBS buffer with a typical concentrations
of ~0.2 mM. Stock solutions of

13

C,

15

N labeled Kdo 2 -Lipid A, and dephosphorylated

Kdo 2 -Lipid A were prepared at 5 mg/mL concentration and extensively sonicated to form
a uniform suspension of the ligands. The ligands were then added to the protein to
produce protein:ligand NMR samples in a molar ratio of 1:1. Recombinant human LBP
(R&D systems) was also present in all samples at a concentration of 2 μM. The
protein:ligand samples were incubated for 30 minutes at 37 ºC to ensure complete
87

binding of ligand. 1H–13C and 1H–15N HSQC spectra were recorded at 17 ºC for each
protein sample with and without the ligand. 1H–13C and 1H–15N HSQC spectra for the
ligands alone were also acquired in PBS buffer. All NMR experiments were carried out
on a Varian VNMRS 600MHz spectrometer at 17 ºC equipped with a cold probe.
Acquired NMR data was processed and analyzed using the Felix software package
(Molecular Simulations).

4.3 RESULTS AND DISCUSSION
4.3.1 PREPARATION AND ISOTOPIC LABELING OF Kdo 2 -LIPID A IN
HEPTOSETRANSFERASE–DEFICIENT Escherichia coli STRAIN
LPS from gram-negative bacteria, whose molecular patterns are recognized by
CD14, represents one of the strongest endotoxin activators in mammals. High-resolution
structural information on specific regions relevant to interactions between LPS and CD14
is highly desirable. However, the presence of multiple highly flexible acyl chains on lipid
A, as well as the micro-heterogeneity of LPS especially in the variable polysaccharide
region, poses considerable difficulties to both crystallization and solution NMR studies of
LPS-receptor complexes. As part of this work, we have developed an efficient protocol to
isotopically label Kdo 2 -Lipid A from the heptosyltransferase-deficient E. coli K-12
mutant WBB06, producing a viable alternative to native LPS because of its similar
biological activity. This has not only permitted us to the probe structural interactions of
Kdo 2 -Lipid A with sCD14 for the first time by solution NMR spectroscopy, it has also
opened up new avenues for NMR structural studies of other endotoxin–receptor
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complexes in the future.
Isotopic labeling of Kdo 2 -Lipid A was accomplished by culturing WBB06 cells in
minimal medium supplemented with 13C labeled carbon and 15N labeled nitrogen sources.
WBB06 showed good growth characteristics in the minimal medium under the labeling
conditions we employed. This made isotopically labeled Kdo 2 -Lipid A amenable to
direct extraction from the cells, a process more efficient and more economical than
chemical synthesis. Additionally, preparation of Kdo 2 -Lipid A, unlike lipid A, does not
require reaction with mild acids which can result in loss of a phosphate group or an acyl
chain (122). Use of a multistep purification scheme enabled efficient removal of
contaminating membrane phospholipids as well as minor hepta-, penta-, and tetraacylated lipid A species, while yielding milligram quantities of highly pure and labeled
Kdo 2 -Lipid A for NMR structural studies. The purified Kdo 2 -Lipid A exhibited
bioactivity on par with the Salmonella minnesota Re 595 rough-type LPS (ReLPS), a
structural homolog to Kdo 2 -Lipid A, in cell-based assays (Figure 4.1).

89

Figure 4.1: Biological activity assay of endotoxin ligands with soluble CD14.
Responses of THP1-Blue cells mediated by purified sCD14 (200 ng/mL) upon stimulation
with three endotoxins, Kdo 2 –Lipid A (1 μg/mL), ReLPS (1 μg/mL), and dephosphorylated
Kdo 2 –Lipid A (1 lg/mL) are shown. Endotoxin stimulation was assessed by measuring the
levels of NF-κB inducible reporter, secreted embryonic alkaline phosphatase (SEAP), using a
SEAP detection medium with absorbance values at 630 nm. Control experiments were the
responses to ReLPS, Kdo 2 –Lipid A, dephosphorylated Kdo 2 –Lipid A, and sCD14 alone.
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Successful incorporation of

13

C and

15

N labels into Kdo 2 -Lipid A was confirmed by

acquisition of 1H–13C and 1H–15N HSQC spectra for the 13C, 15N labeled compound in a
mixed solvent system, which permitted chemical shift assignment of most proton and
carbon resonances in the sugar headgroup and acyl chains (Figure 4.2). Assignment of
the 1H and 13C chemical shifts for Kdo 2 -Lipid A were carried out using standard COSY
(correlation spectroscopy), NOESY (nuclear Overhauser effect spectroscopy), and 1H-13C
HSQC (heteronuclear single quantum coherence) experiments. Assignment of

1

H

chemical shifts was performed using 1H COSY experiments, which show the correlation
of protons within 2-3 bonds of each other. The sequential assignment of the COSY
spectra was facilitated through the use of a predicted 1D 1H-NMR spectra of Kdo 2 -Lipid
A as an initial reference. The 1D spectra was generated using ChemBioDraw
(CambridgeSoft). Ambiguities in the identity of the proton assignments were clarified
using NOESY experiments, which show though-space proton-proton connectivities for
nearby protons. The proton assignments were then used to assign their correlated
chemical shift in a 1H-13C HSQC spectrum. A table of the 1H and

13

C

13

C assignments for

Kdo 2 -Lipid A can be found in Table A1, located in the Appendix.
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Figure 4.2: The 1H-13C HSQC spectrum of 13C isotopically labeled Kdo 2 -Lipid A.

Spectrum of 13C isotopically labeled Kdo 2 -Lipid A in CDCl 3 :CD 3 OD:D 2 O mixed solvent
system (2:3:1, v/v) showing correlations within the sugar headgroup and acyl chain regions.
The inset spectra is a magnified view of a portion of the sugar headgroup region. Chemical
shift assignments for the individual resonances are listed in the Appendix.
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4.3.2 NMR ANALYSIS OF THE Kdo 2 -LIPID A COMPLEXED WITH CD14
To delineate the structural regions of Kdo 2 -Lipid A affected upon binding to
CD14 spectral characteristics in the 1H–13C and 1H–15N HSQC spectra of

13

C,

15

N

isotopically labeled Kdo 2 -Lipid A bound to sCD14 were monitored. In aqueous solution
Kdo 2 -Lipid A forms large aggregates (apparent MW >1 MDa). This causes resonances in
the proton NMR spectrum of Kdo 2 -Lipid A to broaden beyond detection (122, 152).
Kdo 2 -Lipid A, however, binds to CD14 with high affinity (K d ~40nM) as a monomeric
complex in the presence of a catalytic amount of LBP (142). The binding of Kdo 2 -Lipid
A to CD14 as a monomer results in the appearance of well-dispersed signals with the
observed chemical shifts quite similar to those for Kdo 2 -Lipid A in the mixed solvent
system. This allowed the chemical shift assignments of Kdo 2 -Lipid A in the mixed
solvent system to be transferred without ambiguity to the bound complex for analysis of
spectral characteristics.
Analysis of the acyl chain resonances in the 1H–13C HSQC spectrum of
sCD14 complexed Kdo 2 -Lipid A shows that the resonances for the terminal methyl and
methylene groups, referred to as δ and colored light gray in Figure 4.3, are clearly
visible, although with the increased linewidths expected from binding to a 32 kDa protein
(Figure 4.4).

93

Figure 4.3: Chemical schematic of Kdo 2 -Lipid A
structure.
Schematic showing numbering scheme for sugar headgroup and
acyl chain carbons of Kdo 2 -Lipid A.
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Figure 4.4: Comparison of spectral characteristics in the 1H–13C HSQC spectra
of 13C labeled Kdo 2 –Lipid A corresponding to the lower half of the acyl chain
region.
(a) Kdo 2 –Lipid A only in CDCl 3 :CD 3 OD:D 2 O (2:3:1, v/v) mixed solvent system and (b)
Kdo 2 –Lipid A complexed to sCD14 in PBS buffer solution. Differences in linewidths and
chemical shifts between (a) and (b) for terminal methyl and various methylene groups are
shown. The resonances for γ IV and γ VI in Kdo 2 –Lipid A bound to sCD14 are less intense
compared to the methylene resonances in acyl chains and are therefore not visible at contour
levels used in this figure (they are clearly visible in the spectrum at lower contour levels and
not shown for clarity).
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It has been proposed that the mode of lipid A binding involves insertion of its acyl chains
into the large hydrophobic pocket of sCD14, which is lined with the hydrophobic sidechains from the many leucine residues of the leucine-rich repeats. Based on the locations
of leucine residues in the mouse sCD14 crystal structure (75), and the length of the Kdo 2 Lipid A acyl chains, it is likely that the methylene groups are in close proximity to these
residues. Additionally, when compared to the other parts of the acyl chain (see below),
the δ methylene and terminal methyl groups exhibit higher intensity signals and do not
show broadening characteristic of dynamic exchange. This suggests that the lower half of
the acyl chains retain some minor level of movement within the hydrophobic pocket, and
are not, in effect, restricted to a single conformation. Because of this residual flexibility,
the likelihood is that the lower portion of the acyl chains only makes non-specific van der
Waals contacts with the leucine side-chains. Based on the observed spectral
characteristics, we estimate that the lower half of acyl chains in complexed Kdo 2 -Lipid A
exhibiting non-polar interactions possess a length of about 10–12 Å. This corresponds to
the right length for insertion into the hydrophobic portion of the binding pocket in
truncated sCD14.
In contrast to the δ methylene resonances, the α, β, and γ methylene resonances in
the upper portions of the acyl chains are more drastically and differentially affected,
depending on the acyl chain to which they belong. As seen in Figure 4.5 A, the α
methylenes form a group of resonances that resonate downfield between 2.1 and 2.5 ppm.
In the presence of sCD14, the α methylene protons in chains III and V show severe
exchange-broadening effects. The α methylene protons from chain III disappear abruptly,
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while those from chain V exhibit significant resonance splitting and are now only barely
visible (Figure 4.5 B). Furthermore, several closely spaced peaks are observed for the
α protons from chain V indicating presence of multiple conformations in slow exchange
relative to the NMR timescale.
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Figure 4.5: Comparison of spectral changes in the upper acyl chain resonances of
Kdo 2 -Lipid A upon interaction with soluble CD14.

Comparison of spectral characteristics in the 1H–13C HSQC spectra for 13C labeled Kdo 2 –Lipid
A corresponding to upper half of acyl chain region proximal to Lipid A headgroup. (A,C)
Kdo 2 –Lipid A by itself in CDCl 3 :CD 3 OD:D 2 O (2:3:1, v/v) mixed solvent system and (B,D)
Kdo 2 –Lipid A complexed to sCD14 in PBS buffer solution. A representative set of α methylene
resonances and γ methylene resonances are shown.
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On the other hand, the α methylene groups from the remaining chains, IV and VI, are
affected to a lesser extent with no apparent exchange-broadening (data not shown).
The β and γ methylene groups exhibit a similar pattern as the α methylene groups, with
resonances from chains III and V affected the most, followed by chains I and II, with the
resonances from chains IV and VI affected the least. The γ methylenes from chains III
and V again show the presence of multiple peaks, similar to those seen in the α
resonances of these chains (Figure 4.5 A-B), indicating a slowing down of motion upon
interaction with sCD14 (Figure 4.5 C-D). The α, β and γ groups of acyl chains III and V
show the greatest affects of interaction and compose a region in Kdo 2 -Lipid A containing
several polar groups, such as the β-hydroxy and ester linkages, which could contribute
significantly to polar interactions with the hydrophilic rim of sCD14. Additionally, the
1

HN resonances from acyl chains I and III mimic the effects of severe line broadening on

chains III and V, completely broadening out in the presence of sCD14 (Figure 4.6). We
interpret this as involvement in hydrogen bonding interactions for the amine groups,
possibly with polar groups on the hydrophilic rim of sCD14.
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The resonances of the sugar headgroup region of Kdo 2 -Lipid A, which consist of
the 1, 4’-bisphosphorylated D-glucosamine disaccharide sugar headgroup of lipid A plus
the two Kdo sugar units (Figure 4.3), also experience differential spectral changes and
exchange-broadening upon binding to sCD14. In the lipid A sugar headgroup, the
resonances for the entire sugar headgroup broadened out completely when bound to
sCD14, except for the resonances for H5, H5’, H6 ab , and H6’ ab which show broadening
but, unlike the others, remain visible (Figure 4.6). The effect of CD14 binding on the
Kdo sugar resonances is considerably less. In general, they exhibit higher intensity and
narrower linewidths compared to the resonances of the lipid A headgroup. The only
exceptions to this are H2’ and H3’ of the second Kdo unit, which experience significant
broadening (Figure 4.6 F). These protons are located in close proximity to the 4’phosphate group, which is quite important for endotoxic activity and binding interactions
with CD14 (150, 153). It is probable that the movement of the Kdo carboxylic group
located next to the H2’ and H3’ protons towards the 4’-phosphate group could stabilize
any possible interactions of the carboxylic group with positively charged residues on the
amphipathic helices and loops located in the hydrophilic rim of sCD14, or help indirectly
by stabilizing the structure in its immediate vicinity. Movement of the carboxylic group
towards the 4’-phosphate, with a bridging calcium atom, has been noticed previously in
molecular dynamics simulation studies on Kdo 2 -Lipid A (154) lending credence to this
possibility.
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Figure 4.6: Comparison of spectral changes in the sugar headgroup and Kdo
units of Kdo 2 -Lipid A upon soluble CD14 binding.

Comparison of spectral characteristics in the 1H–13C HSQC spectra for 13C labeled Kdo 2 –
Lipid A corresponding to the sugar headgroup region. (A, C, and E) Kdo 2 –Lipid A by itself in
CDCl 3 :CD 3 OD:D 2 O (2:3:1, v/v) mixed solvent system and (B, D, and F) Kdo 2 –Lipid A
complexed to sCD14 in PBS buffer solution. A representative set of lipid A sugar
resonances (H5 and H5’) and Kdo unit resonances (H2 and H2’) are shown.
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The essential role of the phosphate groups in Kdo 2 -Lipid A binding interactions with
sCD14 is also confirmed by our NMR binding experiments utilizing fully
dephosphorylated Kdo 2 -Lipid A. No binding of the dephosphorylated Kdo 2 -Lipid A to
sCD14 was apparent even in the presence of LBP, reinforcing the results from cell-based
activity studies (Figure 4.1).
Observation of strong effects for regions around the phosphates, which includes
the lipid A headgroup, is significant. A sugar headgroup is a common molecular pattern
shared by several endotoxin ligands that interact with sCD14 (138, 139), and is believed
to be important in pattern recognition (17). The lower half of this headgroup is in close
proximity to the polar substituents, the amide and ester linkages, which contain a number
of electronegative oxygen and nitrogen atoms, on acyl chains I, III, and V (Figure 4.7).
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Figure 4.7: Summary of Kdo 2 -Lipid A features affected upon interaction with
soluble CD14.
Review of structural regions in Kdo 2 –Lipid A affected upon interaction with sCD14. Regions
are color coded to show the severity of interaction effects with the most severely affected
regions shown in red, the moderately affected regions in yellow and unaffected regions in
black. Acyl chain portions with upfield shifts in presence of sCD14 are shown in brown.
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Due to the high polar composition of this region, it is conceivable that, together with the
phosphate groups, they form a molecular pattern that could influence the interactions
with the charged/polar residues on the hydrophilic rim of sCD14. There is some
underlying evidence to support this notion. Mutagenesis studies have shown that sCD14
employs hydrophilic regions, largely containing polar and charged residues, to interact
with molecular patterns on LPS (93). These studies demonstrated that certain chargereversal mutations or non-polar residue substitutions greatly diminished CD14’s
interaction with E. coli LPS. The studies also indicated that the hydrophilic regions,
containing polar and charged residues, functioned in determining the efficacy of pattern
recognition of certain LPS species by sCD14. Since the NMR experiments performed in
this study cannot distinguish between direct binding effects and secondary interaction
effects, which result from conformational changes in regions affected by but not directly
involved in binding, we cannot currently ascertain if these regions in Kdo 2 –lipid A are in
direct contact with CD14’s rim. The presences of such direct interactions, however, may
not be uncommon. A recent crystal structure of MD-2 with a known antagonist,
tetraacyltaed Lipid IVa, revealed the presence of a large hydrophobic cavity (155). Lipid
IVa was bound in MD-2’s hydrophobic cavity with the polar moieties of Lipid IVa’s
sugar headgroup tethered via hydrogen-bonds to the polar MD-2 residues at the entrance
of the cavity. The acyl chains of Lipid IVa were inserted deep into the cavity, and
surrounded by hydrophobic MD-2 side-chains. This gives rise to the distinct possibility
that similar types of interactions may well exist, to a certain extent, between lipid A and
sCD14.
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Another interesting finding from the NMR spectral studies of complexed Kdo 2 –
lipid A is the occurrence of intermediate or slow exchange, on the NMR chemical shift
time scale, for many of the affected resonances. In addition, the level of exchangebroadening differs from region to region in Kdo 2 -Lipid A. Given the high affinity of
Kdo 2 -Lipid A and CD14 for each other, this differential dynamic behavior is surprising.
This dynamic behavior suggests that, rather than becoming essentially locked in one
conformation, even in its bound state the ligand still possesses considerable flexibility.
The existence of multiple bound configurations is consistent with the large K off rate
measured for this complex (28). This differential behavior, along with the presence of
multiple resonance splittings, was also observed in the 1H–15N HSQC spectra of

15

N

labeled sCD14 bound to ReLPS (151). While the reasons for this differential behavior are
not entirely clear at this point, a ligand-induced increase in disorder upon the binding of a
hydrophobic ligand has previously been correlated with specificity in ligand recognition
(156). Increased specificity comes as a result of the number of accessible conformations
available to facilitate low-energy contacts between the molecules, thereby providing a
way to fine-tune the binding interactions. In addition, the ability to utilize multiple
individual lower-affinity, lower-energy interactions results in the interaction as a whole
having higher affinity. This is an intriguing possibility to consider for the role of
dynamics in the sCD14:Kdo 2 –lipid A complex, and could have implications for lipid A
pattern recognition. As a result, this dynamic behavior is deserving of greater
experimental scrutiny.
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CHAPTER 5. NMR SPECTRAL MAPPING OF LIPOTEICHOIC
ACID MOLECULAR PATTERNS INTERACTING WITH THE
ENDOTOXIN RECEPTOR CD14

5.1 INTRODUCTION
For many years, gram-negative bacterial infections were the primary cause of
sepsis, but since the end of the 1980’s, gram-positive bacteria have surpassed gramnegative bacteria as the primary cause of sepsis in the US (3). Traditionally, more
attention has been given to sepsis caused by LPS, and by virtue of the fact that LPS is
only found in gram-negative bacteria, this has meant less attention to gram-positive
bacterial sepsis. This preoccupation with gram-negative bacteria and LPS is based on the
long-established viewpoint that gram-negative bacteria are the most common cause of
sepsis (157). This LPS-centered viewpoint was based on an accurate representation of the
cause of sepsis for many decades, but as the use of antimicrobials became increasingly
prevalent in the landscape of sepsis, focus shifted toward gram-positive bacteria as they
began to cause an increasing percentage of all sepsis case (157).
Because gram-positive bacteria do not possess LPS, their source of
immunogenicity has, over the previous years, been a subject of heated debate. However,
it has now become clear that the initial front-runner for the role of gram-positive
endotoxin, peptidoglycan (PGN), is not a ligand recognized by a TLR (51). While it
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should be noted that PGN is recognized via the intracellular immune receptors NOD1 and
NOD2, our interest is in the endotoxin recognized at the first line of defense, the cell
surface (145, 158, 159). The gram-positive cell wall component, now generally
recognized as representing its endotoxin, is lipoteichoic acid (51). LTA has been shown
to be recognized by a signaling complex composed of a heterodimer consisting of TLR2
and TLR6 (27, 30). The activation of the TLR signaling complex for LTA was
discovered to be CD14-dependent, and makes use of LBP to present LTA to CD14 (25).
For this reason, we selected LTA for use to investigate the differential recognition of a
gram-positive endotoxin by CD14.
In an effort to determine the potential contributions of various structural elements
of LTA in its recognition by CD14, we have performed detailed NMR spectral mapping
of isotopically labeled LTA bound to sCD14. This study represents the first structural
characterization of the identity of structural regions in a gram-positive agonist ligand
affected by complex formation with sCD14. This study also provides the first structural
observations of a gram-positive ligand with a host cell receptor in solution, and provides
valuable insights into the mechanism of LTA pattern recognition by sCD14. In addition,
comparison of the results of this study with our previous detailed investigation of Kdo 2 Lipid A’s interaction with CD14 facilitates the further elucidation of pathogen-associated
molecular patterns.
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5.2 MATERIALS AND METHODS
5.2.1 GROWTH, EXTRACTION, AND PURIFICATION OF LIPOTEICHOIC
ACID FROM Bacillus subtilis ATCC 6633™
Bacillus subtilis ATCC 6633™ was grown in M9 media supplemented with 0.1%
casamino acids at 30 °C with agitation (160). Isotopic labeling was accomplished with
the supplementation of

13

C 6 D-glucose into the medium. After ~22-24 hours, the cells

were harvested by centrifugation at 7,000 rpm for 15 minutes. The cell pellet was then
stored at -80 ºC.
Upon thawing of the frozen cell pellet, an equal volume of n-butanol was added.
This mixture was then vortexed followed by brief sonication for ~20 seconds until a fine
solution was generated. The cell pellet–n-butanol mixture was then left stirring at room
temperature. After 30 minutes of stirring, the mixture was centrifuged for 20 minutes at
10,400 rpm to yield a two-phase solution; the aqueous phase was pulled off and
lyophilized. The lyophilisate was resuspended in 15% n-propanol in 0.1 M ammonium
acetate, pH 4.7, buffer and centrifuged at 20,000 rpm for 15 minutes. The supernatant
was subjected to hydrophobic interaction chromatography (HIC) on octyl-Sepharose (49,
50). Individual fractions were checked directly for LTA content using 1D 1H-13C HSQC
NMR experiments. Fractions containing LTA were then pooled and warmed at 40 °C to
evaporate the n-butanol, before being subjected to lyophilization. The lyophilisate was
then resuspended in endotoxin-free water, and dialyzed against endotoxin free water to
remove the ammonium acetate. The final pure samples then had their identity and purity
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re-confirmed using 1D and 2D 1H-13C HSQC experiments. Final purity was >90% as
estimated by NMR.
LTA lipid anchor was produced by hydrolyzing 40 mg of LTA with 0.9 ml of 48
% hydrofluoric acid (HF) for 40-48 hours at 4 ºC. This was followed by neutralization of
the HF with saturated sodium bicarbonate solution and lyophilization. The lyophilisate
was resuspended in 15 ml H 2 O/CH 2 Cl 2 /CH 3 OH (3:3:1) and centrifuged at 3,200 rpm for
7 minutes. The pellet was washed with CH 2 Cl 2 and the water layer with CH 2 Cl 2 /CH 3 OH
(3:1); the organic phases were then combined and evaporated (56). After evaporation, the
remaining precipitate was loaded on an octyl-sepharose HIC column in 15 % n-propanol,
50 mM ammonium acetate, pH 4.7 buffer and the acylated LTA lipid anchor was eluted
from the column using a linear gradient of n-propanol (161). LTA lipid anchor samples
were dialyzed to eliminate any residual ammonium acetate buffer left from HIC.
Cleavage of the polyglycerophosphate chain was confirmed by the disappearance of the
1

H-NMR signals associated with the N-acetylglucosamine and D-alanine substituents of

the polyglycerophosphate chain. Purity of the LTA lipid anchor was also assessed by
comparison to published 1D 1H-NMR spectra (53, 55), and to the predicted 1H-NMR
spectra generated using ChemBioDraw (CambridgeSoft, Cambridge, MA).
5.2.2 NMR MEASUREMENTS ON LTA LIPID ANCHOR BOUND TO
SOLUBLE CD14
Sensitivity-enhanced 1H–13C and 1H–15N HSQC experiments were recorded on a
~1 mg/ml sample of

13

C,

15

N isotopically labeled LTA lipid anchor (143). This sample

was prepared using the mixed solvent system CDCl 3 :CD 3 OD:D 2 O (2:3:1, v/v), and the
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experiment performed at 17 ºC. An unlabeled sample of full-length human sCD14
truncated at residue 152, amino acids 20–171 following the signal peptide sequence, was
prepared in Pichia pastoris as described earlier in Chapter 2. The sCD14 sample used for
the NMR experiments was prepared in PBS buffer with a typical concentration of ~0.2
mM. A stock solution of

13

C,

15

N labeled LTA lipid anchor was prepared at 5 mg/ml

concentration and vortexed vigorously to produce a uniform suspension. The ligand was
then added to the sCD14 to prepare a sCD14:LTA lipid anchor NMR sample in a molar
ratio of 1:1. The sCD14:LTA lipid anchor sample was incubated for 30 minutes at 37 ºC
to ensure complete binding of LTA lipid anchor by sCD14. 1H–13C HSQC spectra were
recorded at 17 ºC for sCD14 in the absence and presence of LTA lipid anchor. All NMR
experiments were carried out on a cold probe equipped Varian VNMRS 600 MHz
spectrometer at 17 ºC. Acquired NMR data was processed and analyzed using the Felix
software package (Molecular Simulations) and/or NMRPipe (162).

5.3 RESULTS AND DISCUSSION
5.3.1 PREPARATION AND ISOTOPIC LABELING OF LIPOTEICHOIC
ACID IN Bacillus subtillis ATCC 6633™
CD14 is capable of recognizing and interacting with cell wall components from
gram-positive bacteria including LTA, which is a strong immune activator in mammals.
Obtaining structural information on the specific regions pertinent to the interactions
between LTA and CD14 would be very beneficial for the elucidation of CD14’s role in
the activation of the immune response. In the course of this work, we have successfully
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developed a protocol for the efficient isotopic labeling of LTA in B. subtilis. In order to
obtain higher cell densities as well facilitate isotope labeling, the B. subtilis growths were
performed in M9 minimal media with additional supplementation with 0.1% casamino
acids. Isotopic labeling was accomplished by simple substitution of 13C 6 -glucose and 15N
ammonium chloride into the growth medium. LTA was extracted using the recently
developed n-butanol method in order to prevent structural decomposition associated with
traditional means of LTA extraction (50). Final purification of extracted LTA was
performed using octyl-sepharose HIC chromatography. Together, these methods produce
milligram quantities of highly purified
labeled LTA lipid anchor.

13

C and

15

N labeled full-length LTA, as well as

This has not only permitted us to probe the structural

interactions of LTA with sCD14 for the first time by solution NMR spectroscopy, it also
poses the possibility for NMR structural studies of other LTA complexes in future.
5.3.2 NMR ANALYSIS OF LIPOTEICHOIC ACID IN COMPLEX WITH
SOLUBLE CD14
A detailed structural investigation of the LTA lipid anchor’s interactions with
CD14 was carried out using multidimensional solution NMR spectroscopy. The results of
the NMR studies with full-length LTA and LTA lipid anchor indicate that the lipid
anchor is sufficient to interact with CD14. The binding of LTA lipid anchor by CD14 has
both similarities and differences from the binding of Kdo 2 -Lipid A. In the 1H-13C HSQC
spectra of CD14-bound LTA lipid anchor, the gentiobiose sugar headgroup resonances
(structural schematic shown in Figure 5.1) broaden out to the point of being
undetectable. This complete broadening of the sugarhead group resonances indicates that
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the interactions are on the intermediate exchange timescale of NMR. This likely indicates
strong interactions with the hydrophilic rim of sCD14. This strong interaction probably
consists of several weaker interactions that together add up to a strong interaction. The
use of multiple weaker interactions by a protein to strongly bind a substrate has been
suggested to contribute to increased binding specificity, and stability by allowing greater
versatility through the ability to selectively form, alter, and break multiple interactions as
needed (163). This could be a mechanism utilized by CD14 in its differential ligand
recognition and binding, as evidenced by the change in exchange rates seen in a number
of resonances.
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Figure 5.1: Structural schematic of LTA lipid anchor.
The numbering scheme for the acyl chains of the LTA lipid
anchor are shown. The spanning δ methylenes are also indicated
in gray.
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The lipid anchor’s two acyl chains likely undergo non-specific Van der waals interactions
with the hydrophobic interior of sCD14 that result in the broadening of the methylene
resonances. The interactions of LTA lipid anchor with CD14 seems to affect a greater
number of resonances than in the case of Kdo 2 -Lipid A. We hypothesize that this may be
because the gentiobiose headgroup of the LTA lipid anchor is smaller than the lipid A
sugar head group and Kdo units. This smaller size may result in a greater number of
interactions between CD14’s hydrophilic rim being spread over fewer ligand features. In
addition, because the acyl chains of LTA and its lipid anchor are attached to the
headgroup by a glycerol linker, and because of the obvious flexibility in the
polyglycerophosphate chain on full-length LTA, the headgroup likely has a greater
potential range of movement. This enables it to fit more extensively along the hydrophilic
rim, and leads to an increase in the broadening and conformational exchange effects for a
majority of the gentiobiose headgroup’s resonances.
An interesting observation was that the α, β, and δ methylene residues of the LTA
lipid anchor show changes in their rates of exchange between conformational states,
much like those seen in Kdo 2 -Lipid A (Figure 5.2). The two α methylenes of the acyl
chain are initially seen as a broad single peak, but upon binding, the single peak
experiences an upfield shift and splits into two resonance peaks, one for each acyl chain’s
α methylene group (Figure 5.2 B). The individual α methylene peaks in the CD14 bound
spectra also show signs of intermediate exchange, as both peaks are broad overlapping
multiplets. The upfield shift, as well as the splitting of the initial α methylene resonance
into individual signals, is indicative of strong interaction with CD14.
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Figure 5.2: Comparison of 1H-13C HSQC spectra of the acyl chain region of
LTA’s lipid anchor upon interaction with soluble CD14.

Comparison of the acyl chain region of 13C isotopically labeled LTA lipid anchor alone (A) in
the mixed solvent system CDCl 3 :CD 3 OD:D 2 O (2:3:1, v/v), and LTA lipid anchor complexed
with sCD14 (B) in PBS buffer.
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The low intensity multiplet observed for the unbound β methylenes of the LTA lipid
anchor indicate they are undergoing intermediate exchange on the NMR timescale. Upon
binding, the β methylene multiplet’s exchange rate quickens, as indicated by the
improved visibility of higher intensity of the bound peak (Figure 5.2 B). However, the β
methylenes are still undergoing conformational exchange at intermediate rates of
exchange, as shown by the retention of a broad overlapping multiplet. When compared to
the other resonances of the acyl chain, the δ methylene groups, which compose the bulk
of the acyl chain’s methylenes (shown in gray in Figure 5.1), have a higher intensity
signal and exhibit fewer signs of exchange broadening. This suggests that the δ
methylenes are not actually restricted to a single conformation, but maintain some
flexibility even when bound within the hydrophobic pocket of CD14. This also implies
that the spanning δ methylenes in the acyl chains likely make only non-specific van der
Waals contacts with the leucine side-chains of the hydrophobic pocket. Furthermore, the
spectral changes observed for the LTA lipid anchor’s δ methylenes appear analogous to
the spectral changes observed in the lower half of Kdo 2 -Lipid A’s acyl chains upon
CD14 binding.
The changes in exchange rates observed in the CD14 bound LTA lipid anchor
once again illustrate that dynamics are a significant part of CD14’s interactions with an
endotoxin ligand. These interactions may be conserved across different ligands as a
mode of recognition. Furthermore, the changes seen in the LTA lipid anchor acyl chains
have a great deal of similarity to those seen in Kdo 2 -Lipid A’s acyl chains. The upper
acyl chain carbons nearest to the headgroup show more significant modulations of their
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dynamics. However, the portions of the acyl chains more distal from the sugar
headgroup, the δ methylenes, show only a minor upfield shift and slight broadening
effects. These changes are to be expected, due to binding to CD14. Together, this
evidence supports the popularly held view that saccharides with charged moieties as well
as acyl chains is a pathogen-associated molecular pattern. This is suggested by the
features of LTA and Kdo 2 -Lipid A affected most strongly during interaction with CD14,
such as the sugarhead group, phosphares, and upper portion of the acyl chains. The role
of charged saccharide groups as molecular moieties common to many PAMPs is further
validated by FLS2 in plants. The features of flagellin seen to interact with the LRRs of
FLS2 are the charged amino acids and hydrophobic amino acid side chains present in
each flagellin monomer. This is demonstrated by the result of investigations of FLS2 that
showed disruption of electrostatic interactions by salt or pH changes, as well as by
mutagenesis experiments significantly reduce flagellin binding. Alanine scanning
mutagenesis studies showed that a loss of hydrophobic regions in the LRRs impacted
FLS2’s ability to interact with flagellin (164). Though there are no acyl chains on
flagellin, the utilization of hydrophobic interactions by FLS2 provides weight to the
proposal that hydrophobic features, primarily in the form of acyl chains or alternatively
amino acid side chains, are another important component in PAMP structural recognition.
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CHAPTER 6. THE ROLE OF DYNAMICS IN THE
INTERACTION OF CD14 WITH ENDOTOXINS

6.1 INTRODUCTION
NMR spectroscopy is well suited to probe the dynamics of a system over a wide
range of time scales from picoseconds to hours. With NMR, it is possible to observe
dynamically active regions in a molecule or macromolecular complex, and to analyze the
dynamics of a specific region or residue at different time-scales. This is accomplished by
measuring the change in certain NMR experimental parameters, such as linewidth, peak
intensity, or chemical shifts, by direct observation of these changes in the NMR spectrum
(165). Both the analysis of the impact of different endotoxin ligands on CD14 and the
analysis of the effects of CD14 on lipid A showed a number of residues which showed
differential line broadening, as seen earlier in Figure 4.5 A-D. Changes in line
broadening could be indicative of a transition from fast rates of exchange between
conformational states to intermediate or slow rates of exchange. A residue that is in fast
exchange between two different environmental states is seen as a single peak. The peak’s
exact position is dependent on the percentage of each state the residue is currently
occupying. If the populations are perfectly split between the two environments, then a
single peak would be seen precisely between where the two possible conformations’
individual peaks would have been seen. If the rate of exchange between two
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conformational states is slow, then two separate peaks would appear corresponding to the
two distinct states. When the rate of exchange is intermediate between fast and slow
exchange rates, the peak broadens significantly as its position is now being averaged over
two or more possible positions. This is sometimes seen as a broad, overlapping multiplet
or the peaks may coalesce and disappear entirely (163).
This study constituted the first direct structural observation of specific residue
combinations in CD14, or any endotoxin binding protein which differentially affect
endotoxin binding. We hypothesize that conformational dynamics in CD14 might provide
specificity to ligand recognition by allowing CD14 to choose conformations that facilitate
low-energy contacts between the molecules and allow fine-tuning of the interactions for
different ligands. This is evidenced by the differential line-broadening detected for
several groups in and around the sugar headgroup of Kdo 2 -Lipid A along with the
existence of multiple conformations, indicating the mode of binding is dynamicallymodulated. This differential broadening, as well as the presence of multiple
conformations is also observed in the 1H-15N HSQC spectra of sCD14 (Figure 3.4) (151).
Interestingly, upon formation of the CD14-endotoxin complex, there are no indications
either in the 1H-15N HSQC spectra or in circular dichroism spectra that reveal any
significant conformational changes in CD14. The lack of global conformation changes in
CD14’s structure upon binding in conjunction with the dynamics revealed by differential
line broadening strongly implies that dynamics must play a key role in the recognition
and binding of the structurally diverse endotoxin ligands of CD14. To analyze whether
changes in temperature and pH can modulate CD14’s dynamics in a manner similar to
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those seen upon binding of different endotoxin ligands, we have performed a series of pH
and temperature dependence studies.

6.2 MATERIALS AND METHODS
6.2.1 EXPRESSION AND PURIFICATION OF ISOTOPICALLY LABELED
SOLUBLE CD14
Isotopically labeled samples of a truncated version of full-length human sCD14
sequence consisting of the 152 N-terminal residues (amino acids 20–171), after the signal
peptide sequence, were prepared in Pichia pastoris. Isotopic labeling was accomplished
by supplementing the expression medium with

15

N ammonium sulfate. The expression

conditions and purification procedures are the same as described earlier in Chapter 2.
6.2.2 NMR STUDIES ON THE TEMPERATURE AND pH DEPENDENCE OF
SOLUBLE CD14
The

15

N labeled sCD14 sample used for the temperature dependent NMR

experiment series was prepared in PBS, pH 8.9 buffer containing 0.5M D 5 -Glycine with
a sCD14 concentration of ~0.2 mM. 1H-15N HSQC spectra were collected on this sample
at 17, 27, and 37 ºC. Prior to the start of each NMR experiment, the sCD14 sample was
allowed to equilibrate, in the spectrometer, at each new temperature increment for 15
minutes.
The

15

N-labeled sCD14 sample utilized for the pH dependent experiment series

was prepared in PBS pH 7 buffer containing 0.5 M D 5 -glycine. For each pH investigated,
a 5 ml volume of PBS pH 7.0 containing 0.5 M D 5 -glycine was adjusted to pH 8.0, and
9.0 by the dropwise addition of 6 M potassium hydroxide. Adjustment of the PBS’s pH
was monitored using an automatic temperature correction pH probe (Denver
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Instruments). The sCD14 sample’s pH was raised incrementally to each new pH level by
performing buffer exchange using an Amicon Ultra-4 centrifugal filter unit (Millipore,
Billerica, MA). All of the pH dependent NMR experiments were carried out at 37 ºC.
Sensitivity-enhanced 1H-15N HSQC spectra were recorded at each temperature
and pH for the protein samples (143). Data was collected with 1024 complex points in the
direct dimension and 64 complex points in the indirect dimension for the HSQC
experiments. All NMR experiments were carried out on a Varian VNMRS 600 MHz
spectrometer equipped with a cold probe. Acquired NMR data was processed and
analyzed using NMRPipe (162) or the Felix software package (Molecular Simulations).

6.3 RESULTS AND DISCUSSION
6.3.1 ENHANCEMENT OF SOLUBLE CD14 SOLUTION STABILITY
The need for a sCD14 sample with good stability over an extended timespan was
an important factor in being able to perform lengthy experiment series. Previously, we
had seen that ligand-free sCD14 at high concentration had a limited lifespan, especially at
higher temperature, and would begin to unfold and aggregate after ~6 hours. This
reduced stability was compensated for in our earliest studies by running NMR
experiments at low temperature, 17 ºC (151). However, with the addition of osmolytes, a
protein’s stability can often be increased, and therefore its lifespan in its folded form can
be extended. The manner by which osmolytes extend the useful life of a protein is not
fully understood, but is thought to work by helping maintain the protein’s folded structure
through preferential hydration of the protein, which is entropically favorable for the
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folded state (166, 167) However, the use of high concentrations of osmolyte in an NMR
sample would result in the introduction of new and overwhelmingly large signals into the
NMR spectra. This requires that osmolytes used in NMR be perdeuterated and, given its
small size and low-cost, perdeuterated glycine is an excellent choice (167). 0.5 M D 5 glycine was determined to be an optimum concentration for maintaining CD14 stability,
and was added to the PBS buffers used in the sCD14 pH and temperature dependent
studies. This extended the lifetime of the sCD14 samples used from hours to days.
6.3.2 TEMPERATURE AND pH DEPENDENT CHANGES IN THE NMR
SPECTRA OF CD14
In recent years, the importance of dynamics in a protein’s ability to function has
been shown to be absolutely critical. Without the dynamics present in regions of many
proteins’ structures, they would no longer be capable of functioning effectively if they
functioned at all (168). The results of our NMR structural studies have demonstrated that
CD14 has a significant amount of dynamic motion present in its structure. CD14 was
observed to sample multiple conformational states as evidenced by the splitting of single
resonances into multiple resonances. In our previous analysis of ligand recognition by
CD14, we proposed that dynamics plays a role in modulating the specificity of CD14’s
interactions with its endotoxin ligands. This is in line with studies that have shown an
increase in the overall protein backbone conformational entropy upon binding of a
hydrophobic ligand. This was correlated with increased stabilization of the protein-ligand
complex, as well as greater ligand specificity (156). By carrying out NMR studies of
isotopically labeled sCD14 under varying temperature and pH conditions, the range of
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possible dynamic behavior in CD14 could be investigated, and compared to the
endotoxin binding induced changes in dynamics. A number of the dynamic CD14
resonances exhibited multiple broad, overlapping peaks characteristic of intermediate
exchange rates. Based on the intensity of the individual peaks composing the multiplet, it
can be discerned that the different populations represented in the multiplet are actually
differing conformational states. By collecting 1H-15N HSQC spectra of CD14 over a
series of incremental temperature increases, we observed temperature-dependent
modulations of the range of conformational states that some resonances were able to
sample. This was evidenced by changes in the intensities of specific peaks within the
splitting indicated by the bracket in Figure 6.1.
An increase in temperature generally has more effect on the flexible regions of a
protein’s structure. Higher temperatures cause the exchange rates to shift toward faster
exchange regimes. Changes in temperature can also effect the formation and dissociation
of hydrogen bonds, as well as changing the entropy of the system, which will favor
protein unfolding (169). At low temperature, the conformational states being sampled by
the indicated CD14 resonance are quite varied in terms of their populations as seen by the
multiple peaks (Figure 6.1). However, as the temperature is raised, the populations in
each conformations being sampled shift, as indicated by the shift of intensity from the
upper peak of the multiplet to the lower peak at 27 ºC. As the temperature is increased
further, the intensity shifts from the lower peaks of the multiplet back to the upper peak at
37 ºC. These shifts likely indicate that those specific conformations are not as highly, or
possibly not as easily, populated at low temperatures, but as the temperature is raised,
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these conformational states become progressively more favorable for occupancy. This is
illustrated by the shift of intensity to different positions within the multiplet at 27 ºC and
37 ºC. The conformation favored at 27 ºC is not the same conformation favored at 37 ºC.
In addition, as the temperature changes this results in changes in the local
environments experienced by a residue, this change in environment also causes change in
the chemical shift of the residue this is illustrated in Figure 6.1, by the shift of intensity
in the multiplet down and toward the left at 27 ºC and the up and toward the right at 37
ºC.
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Figure 6.1: Temperature-dependent changes in 1H-13C HSQC spectrum of CD14.
The bracket indicates the multiplet showing representative temperature-dependent changes
over the tested temperature range. Also, visible in the lower portion of the spectra, are the
temperature-dependent appearance and disappearance of several additional resonances.
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In addition, by adjusting the pH of the sample, the transitions between various
conformational states for some resonances could also be modulated (Figure 6.2).
Changes in pH can affect the charge and electrostatic interactions in a protein by causing
the protonation or deprotonation of side chains; this in turn can directly affect the
stabilization of different conformational states (170). By incrementally increasing the pH
of the sCD14 sample, we observed the sampling of a series of conformational states
evidenced by the shift of peak intensity among the peaks composing the multiplet. This
is most clearly illustrated by the multiplet indicated in Figure 6.2 by the bracket. As the
pH is changed, the more intense peaks of the multiplet at pH 7.0 lose intensity while the
less intense peaks gain intensity, as seen at pH 8.0. At pH 9.0 the distribution of intensity
between the peaks of the multiplet has reversed, with the originally less intense peaks at
pH 7.0 now being the most intense at pH 9.0, and the initially intense peaks seen at pH
7.0 completely disappearing at pH 9.0. In addition, the number of peaks observed in the
multiplet decreases, suggesting that fewer distinct conformational states are now
accessible. At pH 9.0, only two conformations appear to be favored, and the dynamic
exchange between other possible conformations is no longer discernable. Once again we
see that CD14 is sampling multiple different conformational states, and that through
incremental pH adjustments we are able to influence what conformations are favored.
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Figure 6.2: pH-dependent changes in 1H-13C HSQC spectrum
of soluble CD14.
The bracket indicates the resonance showing the greatest pH-dependent
changes, over the examined pH range.
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Our ability to influence what conformational states a resonance is able to sample
provides further corroboration that CD14 is indeed undergoing dynamic conformational
sampling. This correlates with our previous studies, which indicated that the interaction
of CD14 with its ligands had a dynamic component. While the identity of the residues
showing dynamic behavior is not known at this point due to a lack of CD14 resonance
assignments, the significance of the observed modulations still carries substantial
implications for how CD14 interacts with such a diverse array of ligands. The presence of
structurally dynamic regions and residues might help in explaining how CD14 is able to
differentially recognize endotoxin ligands. The contribution of conformational dynamics
to protein function and ligand binding specificity has been highlighted by a number of
recent studies. These studies have shown that the internal dynamics of a protein varied
depending on what ligand was bound, and this contributed substantially to ligand
specificity as well as to the formation of high-affinity protein-ligand interactions (171173). The multiple conformations populated by CD14 suggest that CD14 may use
different conformational states to either aid in binding specific ligands, or that these states
may represent distinct states induced in CD14 by ligand binding.
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CHAPTER 7. USE OF A SPIN-LABELED LIPID A TO
MEASURE DISTANCE RESTRAINTS FOR LIPID A IN
COMPLEX WITH CD14

7.1 INTRODUCTION
For many years now, the popularity of utilizing spin-labels in solution NMR to
collect long distance restraints, and map the binding interactions of protein-ligand
complexes has been growing. The application of spin-labels to use in protein-ligand
interactions allows for observations of residue-specific binding in large macromolecule
complex, as well as detailed distance information to be collected. The principle that
allows a spin-label to be used for this is paramagnetic relaxation enhancement (PRE)
(174-176). In general terms, the spin-label’s free radical, a paramagnetic center, has the
ability to interact with any neighboring proton within 15-25 Å. This dipolar interaction of
the free electron with surrounding protons causes the resonance signal for the affected
protons to relax more rapidly than in normal conditions. In NMR, the faster the relaxation
of a given nuclear spin, the broader /weaker its signal appears, and the closer to the spinlabel a spin is, the greater the broadening. Because the magnitude of the paramagnetic
relaxation enhancement is directly related to distance from the free radical, it is possible
to calculate physical distances between a given interacting proton resonance and the spinlabel (174, 177). The calculation of the distances is accomplished by measuring the
change in peak intensity in the presence and absence of the spin label. This technique is
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convenient in that it does not require multiple, perfectly matched samples in a spinlabeled and non-spin-labeled versions. First, a spectrum is collected on the spin-labeled
complex in its oxidized, paramagnetic state followed by addition of a reducing agent to
the sample, and collection of a spectrum of the complex with the spin-label in a reduced,
diamagnetic state (178).
Though a high-resolution crystal structure of mouse CD14 has been solved,
revealing a great deal of new data about CD14 and its structure, the lack of a bound
endotoxin ligand ultimately limits the overall usefulness of the structure (75). This
limitation is further compounded by the significance of endotoxin binding in CD14’s
function. CD14’s binding abilities form the foundation of its critical differential
recognition of endotoxin, and thus its ability to activate different TLR’s. Therefore, a
ligand bound CD14 structure is of vital interest. Our recent investigations have greatly
expanded the scope of structural information regarding CD14’s ability to differentially
recognize endotoxin-associated patterns and provided detailed insights into the specific
structural elements recognized in an agonist ligand (151, 179). However, the lack of a
structure for a CD14-ligand complex is a conspicuous gap in the field of knowledge for
CD14. A high-resolution structural model of CD14 with an agonist would provide
information that would greatly strengthen the understanding of how CD14 functions, and
provide clues into how the transfer of an endotoxin from CD14 to its requisite TLR might
take place. At this time, NMR assignments for CD14 are not available, but NMR
assignments are available for 13C 15N isotopically labeled Kdo 2 -Lipid A and they transfer
directly to lipid A. Our ability to produce isotopically labeled lipid A in large amounts
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with high purity afforded us the opportunity to produce a spin-labeled and isotopically
labeled version of lipid A. Spin-labeled,

13

C

15

N lipid A provides a way to collect

paramagnetic relaxation enhancement-based distance restraints, which offer a means to
solving the structure of lipid A’s bound conformation. Determination of lipid A’s bound
conformation would allow a high-resolution CD14-lipid A structure to be modeled. In an
effort to achieve this goal, we have undertaken the preparation and characterization of
spin-labeled,

13

C labeled lipid A, and collected reduced and oxidized 1H-13C HSQC

experiments on spin-labeled lipid A-CD14 complex in reduced and oxidized forms.
These experiments have been used to calculate a partial set of intermolecular distances
for bound lipid A.

7.2 MATERIALS AND METHODS
7.2.1 PREPARATION, SPIN-LABELING, AND PURIFICATION OF 13C LIPID
A
13

C 15N isotopically labeled Kdo 2 -Lipid A was produced using the E. coli mutant

WBB06 as described previously (179). Preparation of lipid A from

13

C isotopically

labeled Kdo 2 -Lipid A was prepared as described in Chapter 2.
Spin labeling of lipid A was performed following the protocol outlined by
Bretscher et al. (180). In order to attach the nitroxide spin-label 3-carboxy proxyl (Sigma
Aldrich, St. Louis, MO) to lipid A it was converted to an acid chloride form. This was
performed by dissolving 12.5 mg of 3-carboxy proxyl in 750 μl benzene in an amber vial
with a Teflon septa. Also added to the solution was 0.27 mmol pyridine and 0.37 mmol
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thionyl chloride. This mixture was stirred for 1 hour at room temperature, open to the air
via a needle inserted in the septa. All solvents were evaporated under a stream of nitrogen
gas then resuspended in 250 μl chloroform. In a fresh vial, 1 mg of

13

C

15

N lipid A,

determined by weighing of the sample on a Sartorius MC1 scale accurate to 0.1mg in a
pre-weighed tube, was resuspended in 1 ml chloroform, and 3.2 μl 3-carboxy chloride
acid solution, and 0.2 μl triethylamine. This reaction solution was sealed and incubated
with stirring for 20 hours at 4 ºC. After incubation, the sample was dried under a stream
of nitrogen gas and resuspended in endotoxin free water. Unreacted spin-label was
removed from the resuspended sample by repeated washes, and followed by loading onto
a NAP-25 column (GE Healthcare). The spin-labeled lipid A was eluted following the
recommended procedure. Failure to adequately dilute and sonicate the sample prior to
loading on the NAP-25 column can result in the lipid A aggregate remaining on top of the
columns upper frit. After elution, the upper frit was washed with endotoxin free water,
and the wash checked for spin-labeled lipid A. If the sample was to be stored for an
extend time before use it was lypholized and kept at -20 ºC.
7.2.2 CHARACTERIZATION OF SPIN-LABELED 13C LIPID A BY EPR AND
MALDI-TOF
The presence of lipid A in the spin-labeled lipid A sample was verified by
collecting one dimensional 1H-13C HSQC spectra of the sample in the mixed solvent
system CDCl 3 :CD 3 OD:D 2 O (2:3:1, v/v) at 25 ºC using a cold probe equipped Varian
VNMRS 600 MHz spectrometer. The presence of lipid A was confirmed by the
characteristic lipid A acyl chain peaks in the 1H-13C HSQC spectra.
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The presence and magnetic state of the spin-label was confirmed by electron
paramagnetic resonance spectroscopy. The spin-labeled sample was resuspended in a
minimal volume of endotoxin free water and placed in a quartz capillary tube. All
experiments were carried out at 37ºC on a Bruker EMX X-Band spectrometer equipped
with a temperature control module.
MALDI-TOF mass spectrometry was used to ensure that only a single spin label
was being attached to the lipid A molecule. 2,5-dihydroxybenzoic acid (DHB) was
selected for use as the matrix and was prepared in methanol at a concentration of 30
mg/mL. 0.5μL of matrix was spotted onto the target plate and allowed to dry before
addition of 0.5μL of spin-labeled 13C 15N lipid A, at ~5 mg/mL in CH 3 OH:CHCl 3 :H 2 O
(3:2:1 v/v). Deuterated versions of the three solvents were used in NMR samples (181,
182). An external calibration was performed using Bruker’s peptide calibration standard
II prepared per the manufacturers instructions, and applied to the target plate in the same
manner as the lipid A samples. MALDI-TOF was preformed on a Bruker-Daltonics
microflex system in positive detection mode. MALDI-TOF of samples was performed
following confirmation of the spin-label’s presence by EPR and lipid A by NMR.
Because the area under an NMR resonance peak is proportional to the number of
protons represented by the resonance, the ratio of spin-label to lipid A can be determined
based on comparison of the integral values for peaks known to belong to lipid A and 3carboxy proxyl. This allowed NMR conformation of the attachment of a single 3-carboxy
proxyl to lipid A by integration of the 1H-NMR of a fully reduced spin-labeled lipid A
sample in CH 3 OH:CHCl 3 :H 2 O (3:2:1 v/v). The 1H-NMR spectrum was processed and
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the peaks integrated using MestReNova (Mestrelab Research). In order to minimize error
in the automated intensity measurements the signal suppression function was applied to
the residual water, methanol, and chloroform peaks, followed by a polynomial baseline
correction. The integrals were then measured using MestReNova’s automated integration
method, and the integral values were normalized to the methyl proton signal of Lipid A’s
acyl chains.
7.2.3 NMR MEASUREMENTS OF SPIN-LABELED 13C LIPID A IN
COMPLEX WITH SOLUBLE CD14
Unlabeled samples of the 152-residue truncation of full-length human sCD14,
amino acids numbering 20–171 without the signal peptide sequence, were prepared in
Pichia pastoris as described in Chapter 2. The samples used for the NMR experiments
were prepared in PBS buffer pH 7.4 with typical concentrations of ~0.25 mM. A stock
solution of spin-labeled 13C, 15N lipid A was prepared at 5 mg/mL concentration in 99%
D 2 O and briefly sonicated to ensure uniform resuspension. Spin-labeled 13C lipid A was
then added to the protein in a molar ratio of 1:1.5 and incubated for 45 minutes at 37 ºC
to ensure complete binding of ligand. The 1.5 ml tube containing the sample was then
placed in a vacuum flask and degassed for 15 minutes under vacuum. Reduction of the
spin-label was carried out by addition of sodium dithionite, Na 2 S 2 O 4 , to the sample in a
12:1 molar ratio of Na 2 S 2 O 4 to spin-label. Elimination of the sample’s EPR signal was
monitored and taken as an indication of reduction of the spin-label’s free radical, which
also allowed monitoring for exhaustion of the transient sulfur dioxide anion radical seen
upon addition of ice-cold Na 2 S 2 O 4 to the sample (183). 1H–13C HSQC were recorded at
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37 ºC for the oxidized and reduced sample. Data was collected with 1024 complex points
in the direct dimension and 72 complex points in the indirect dimension. All NMR
samples were run in 4 mm D 2 O matched Shigemi tubes (Shigemi, Allison Park, PA).
Experiments were carried out on a Varian VNMRS 600 MHz spectrometer equipped with
a cold probe. NMR data was processed and analyzed using NMRPipe (162) Polynomial
baseline corrections was applied to minimize baseline distortions near the water peak. An
exponential window function was applied to the direct dimension, and a 90º-shifted
squared sinebell window function was used for the indirect dimension. Distances were
calculated based on peak intensities as described in detail below.

7.3 RESULTS AND DISCUSSION
7.3.1 PREPARATION AND CHARACTERIZATION OF SPIN-LABELED 13C
15
N LIPID A
Using the methods and protocols described earlier in this dissertation, highly
purified

13

C

15

N Kdo 2 -Lipid A was produced, hydrolyzed with 1% acetic acid, and re-

purified yielding high purity 13C 15N lipid A. The choice to attach the spin-label to lipid A
as opposed to Kdo 2 -Lipid A provided several advantages. One advantage was that upon
removal of the Kdo 2 unit, lipid A had only a single primary alcohol, located distal to the
C6’ position (refer to Figure 1.3). The labeling protocol described in Bretscher et al.
takes advantage of this by using conditions that highly favor conjugation of the spin-label
to a primary alcohol (180). In addition, the 3-carboxy proxyl spin label has a molecular
weight and relative size on par with a single Kdo unit. This suggested that the attached
spin-label should not interfere with binding by CD14, and should easily be
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accommodated in the CD14 binding pocket. This proved true based on the observation of
lipid A signals in the 1H-13C HSQC spectra of spin-labeled

13

C

15

N lipid A bound by

sCD14. Had binding not occurred, no lipid A signals would have been seen due to spinlabeled lipid A forming a micelle in aqueous environments. These micelles have a high
molecular weight >1MDa, rendering them unobservable in NMR
EPR analysis of the spin-labeled lipid A in the mixed solvent system
CH 3 OH:CHCl 3 :H 2 O 3:2:1 (v/v) as well as in endotoxin-free water revealed that the spinlabel was present and in an oxidized state as indicated by the presence of a signal in the
EPR spectrum (Figure 7.1). The absence of a signal would have indicated either failure
of the conjugation reaction or the reduction of the spin-label at some early point. In the
case of a weak EPR signal, this would could be a sign of incomplete labeling of lipid A
population in the spin-labeling reaction. A weak signal could also be a result of line
broadening. Analysis of spin-labeled lipid A samples in the mixed three solvent system,
which dissolves lipid A micelles, as well as in endotoxin-free water, which favors micelle
formation, allowed for lineshape changes due to solvent environment or micelle
formation to be observed. This was then taken into account when estimating whether the
observed EPR signals met the expected signal strength, based on the concentration of
spin-labeled lipid A being used.
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Figure 7.1: EPR spectra of Spin-Labeled Lipid A in aqueous and organic
solvent.
Comparison of signal characteristics in PBS, pH 7.4, (A), and in CH 3 OH:CHCl 3 :H 2 O
(3:2:1 v/v) solvent mixture (B). Both spectra are indicative of fast regime rotational
correlation times, but the environment occupied by the spin-labels differ, as seen by
the broader lineshapes in the mixed solvents.
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To check that only a single spin-label was being attached per lipid A molecule,
samples were examined using MALDI-TOF mass spectrometry. The expected weight of
13

C

15

N lipid A with a single 3-carboxy proxyl spin label attached is ~2061.63 Da. The

MALDI-TOF spectra showed a number of peaks corresponding to lipid A fragmentation
variants common to MALDI-TOF analysis (182). MALDI-TOF of lipopolysaccharide
and lipid A samples can be problematic due to the hydrophobic nature of the sample,
which leads to poor ionization and requires the use of higher power settings. The use of
higher power settings leads to greater desorption fragmentation of the lipid A molecule.
The most common fragmentation variants resulting during MALDI-TOF analysis of lipid
A and Kdo 2 -Lipid A samples are the loss of acyl chain VI. Additionally, in the case of
Kdo 2 -Lipid A, MALDI-TOF analysis also leads to the loss of the Kdo 2 units (181, 182).
Since the spin-label is attached at the primary alcohol where the Kdo 2 unit was attached,
it is reasonable to presume that loss of the spin-label could occur in spin-labeled lipid A
samples in much the same way as the Kdo 2 units could be lost from a Kdo 2 -Lipid A
sample. Taking this into consideration, the major peaks located at 1837.90 and 1854.90
m/z correspond to a single spin label attached to a lipid A that has the lost acyl chain VI
(~226Da) (Figure 7.2). The small difference between the two is roughly equivalent to the
presence or absence of a sodium ion. There were also peaks of 2062.03 and 2054.04 m/z
present correlating to a fully intact spin-labeled 13C 15N lipid A molecule in the presence
or absence of a sodium ion. The peaks at 1613.51 and 1631.50 m/z match the weight of
lipid A that has lost acyl chain VI and either lacks or loses the spin-label during
ionization by the laser (Figure 7.2).
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Figure 7.2: MALDI-TOF spectra of spin-labeled 13C 15N Lipid A.

The major peaks seen in spin-labeled 13C 15N lipid A. Each inset spin-labeled lipid A
schematic is positioned near its representative peaks. Red boxes indicate the position of the
lost spin-labeled lipid A fragment(s). Inset (A) shows the intact spin-labeled lipid A structure,
(B) shows the most common fragmentation artifact, loss of acyl chain VI. Inset (C) shows the
second most common desorption artifact; a lipid A which has lost the spin-label and acyl chain
VI.
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7.3.2 NMR ANALYSIS OF SPIN-LABELED LIPID A IN COMPLEX WITH
CD14
Initial experiments on the CD14-spin-labeled lipid A complex utilized PBS, pH
8.9, containing 2 M D 5 -glycine. This particular buffer provided a longer usable lifetime
for sCD14 NMR samples, especially ligand-less sCD14 samples run at higher
temperatures. However, over the course of the spin-labeling study, it became apparent
that this buffer, for some unknown reason, impeded the complete binding of ligand.
Additionally, the extensive washing steps, necessary to ensure the sample had no residual
protonated glycine present because of the use of PBS, pH 8.9, 2 M glycine buffer to
increase long-term storage life of sCD14 samples, were resulting in a loss of sample and
stability rather than an extension.
The most problematic aspect of using basic pH conditions in conjunction with
glycine was the fact that this buffer hampered complete reduction of the spin-label by
Na 2 S 2 O 4 or ascorbic acid. When a free radical is fully reduced and the spin-label is in a
diamagnetic state, it is no longer detectable by EPR. This complete elimination of the
EPR signal was used as the standard by which the reduction of the NMR sample was
considered complete.
Earlier attempts at performing the oxidized and reduced NMR experiments
required an astonishingly high amount of the reducing agent ascorbic acid. Due to the
large NMR signals introduced into the spectra by dehydroascorbic acid, an oxidized form
of ascorbic acid, it was decided to switch to sodium dithionite, Na 2 S 2 O 4 , which has no
1

H or

13

C NMR signals. However, even when using Na 2 S 2 O 4 the amount of reducing

agent needed was well beyond the normal ratios typical of this type of experiment. The
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use of ascorbic acid to reduce the spin-label ultimately precipitated the investigation that
led to discontinuing the use of the PBS, pH 8.9, 2 M glycine buffer conditions for spinlabeled lipid A-CD14 samples. This was necessitated by an experiment in which a
sCD14-spin-labeled lipid A sample used to collect an oxidized and reduced 1H-13C
HSQC data set changed colors. Initially, the sample had the appearance of water, before
and after the collection of the oxidized 1H-13C HSQC spectra. After the sample was
reduced with ascorbic acid the reduced 1H-13C HSQC spectra was collected. Upon
removal of the sample from the spectrometer, it had turned a bright brownish-red. Upon
further investigation we discovered that ascorbic acid and glycine in basic pH conditions
has been utilized in certain industrial food coloration procedures to make red, yellow, and
brown color pigments (184, 185).
The appearance of the red color pigments in the reduced NMR sample led to an
investigation to ascertain the effect of pH and glycine on the amount of reducing agent
needed to fully reduce spin-labeled lipid A. A series of 50 μM spin-labeled lipid A
samples were prepared for EPR in one of four different buffers. Those buffers were PBS
pH 7.4, PBS pH 7.4 with 2 M glycine, PBS pH 8.9, and PBS pH 8.9 with 2 M glycine,
the amount of Na 2 S 2 O 4 needed to reduce the sample was monitored under each buffer
conditions. The sample in PBS buffer, pH 8.9 with 2 M glycine required a final Na 2 S 2 O 4
concentration of 34 mM to fully reduce, but in PBS pH 8.9 lacking glycine it took only
15 mM. In the identical pair of experiments performed in PBS pH 7.4 with and without 2
M glycine, the sample with 2 M glycine required 22 mM Na 2 S 2 O 4 to fully reduce the
free radical whereas without glycine the same sample required only 15 mM. Additionally,
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attempts to use ascorbic acid as the reducing agent required similar quantities, and its use
would have still added undesirably large NMR signals into the reduced 1H-13C HSQC
spectra. The incompatibility of the PBS, pH 8.9, 2 M glycine buffer with the reduction of
the spin-label became apparent after these experiments.
During initial reduction trials, the addition of the reducing agent rapidly resulted
in the loss of the typical 3-signal EPR splitting, illustrated by Figure 7.1, but resulted in a
persistent central signal. This signal was eventually determined to be caused by the
presence of sulfur dioxide anion radicals (183, 186). Careful degassing and the use of the
minimum reducing agent possible to fully reduce the spin-label, in conjunction with short
incubations open to the air, resulted in the elimination/exhaustion of the sulfur dioxide
anion radical signal. It was also found that addition of chilled Na 2 S 2 O 4 to the slightly
warmer CD14-spin-labeled lipid A sample increased the anion radical signal seen.
Fortunately, this signal was only short lived.
By preparing spin-labeled

13

C

15

N lipid A-sCD14 NMR samples in PBS pH 7.4

buffer, better binding of spin-labeled lipid A was seen as indicated by increased signal
intensity in 1H-13C HSQC spectra. The use of PBS pH 7.4 also led to a faster more
complete reduction of the spin-label using significantly lower concentrations of
Na 2 S 2 O 4 .
Successful collection of an oxidized and a reduced 1H-13C HSQC spectra from the same
sample allowed for resonance intensities to be measured for a number of peaks.
7.3.3 CALCULATION OF INTENSITY BASED DISTANCES FOR CD14
BOUND SPIN-LABELED LIPID A
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Calculation of the distance between individual lipid A’s protons and the unpaired
electron of the spin label were based on measurement of the intensities of the lipid A
resonances in the presence of the oxidized spin-label, and again after reduction of the
spin-label to its diamagnetic state (178). Collection of 1H-13C HSQC spectra in the
oxidized and reduced state allowed the change in peak intensities between the two states
to be quantified using NMRpipe (162). These intensities in turn are used in the following
equation, where I osl and I rsl are the peak intensities of resonances in the oxidized and
reduced states, and t is the total time during the insensitive nuclei enhanced by
polarization transfer (INEPT) period of the HSQC pulse sequence.

⎛1⎞
⎛1⎞
1 ⎛ I rsl ⎞
−
=
ln⎜ ⎟
⎜ ⎟
⎜ ⎟
T
t
T
⎝ 2 ⎠osl ⎝ 2 ⎠rsl
⎝ Iosl ⎠

(1)

The value obtained for (1/T 2 ) osl – (1/T 2 ) rsl using equation 1 was then used in equation 2,

⎞
⎛1⎞
⎛1⎞
K⎛
3τ c
⎟
⎜ ⎟ − ⎜ ⎟ = 6 ⎜⎜ 4 τ c +
2 2 ⎟
1
+
ω
τ
⎝ T2 ⎠osl ⎝ T2 ⎠ rsl r ⎝
( H c )⎠

(2)

in which τc is the rotational correlation time for CD14, ω H is the Larmor frequency, r is
the distance of the nucleus from the unpaired electron, and K is a compilation of
constants related to spin properties of the system whose value is 1.23 x 10-32 cm6s-2 (178).
In order to use equation 2, the value of rotational correlation time ( τc ) must be
known. Because we lack direct NMR measurement of the τc for CD14, the Stokes
equation, given below, was used to determine the value of τc (187).
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4πηw rH3
τC =
(3kBT)

(3)

Where ηw is the viscosity of the solvent, in this case the viscosity value of PBS pH 7.4 at
37 ºC was 0.713 mPa·s (188). T is the temperature,

kB

is the Boltzmann constant, and

rH

is

the hydrodynamic radius of CD14 calculated using the equation given below (187).
1/ 3

⎡ 3V M ⎤
r
rH = ⎢
⎥
4
π
N
⎣(
A )⎦
The symbol

V

+ rw

(4)

is the specific volume of the protein, assumed to be 0.73 cm3/g, N A is

Avogadro’s number,

M

r

is the molecular weight of the protein, and

rw

is one half of the

hydration shell, ~1.6Å.
The τC value calculated for CD14 using equation 3 is not as accurate as could be
calculated for other proteins. This is because the equation is meant to be used to calculate
the τC for proteins with spherical/ellipsoid shape, whereas CD14 does not have that shape.
Calculation of τC using measurements of CD14’s longitudinal relaxation time (T 1 ) would
be more accurate, but the lack of CD14 assignments prevents the use of T 1 values to
calculate τ C . There is an additional source of error in the τC calculation that being the
calculated value of

rH ,

though the error in this calculation is reduced due to the only

unknown value being used for the hydration shell ( rW). An accurate hydrodynamic radius
and even a value for τC could have been readily measured using a dynamic light scattering
instrument, without the need for isotopically labeled proteins samples, but unfortunately
one was not available within the time constraints needed to complete this work.
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However, the use of these four equations allowed for the calculation of distances
for each identifiable lipid A resonance, seen in the oxidized and reduced 1H-13C HSQC
spectra, of sCD14 bound spin-labeled 13C lipid A. The calculated distances are shown in
Table 2, and Figure 7.3 shows the lipid A atoms which correspond to the measured
distances. The standard error of the mean was calculated to be 0.8 Å, and the sample
standard deviation was 2.7 Å. Given the plausible level of error in the τC and

rH

values

the total error values of 3.5 Å, seem, realistic given the unknown level of error in the τC
and

rH

values.
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Table 2: Intermolecular distances calculated for spin-labeled lipid A

Residue
C1
C4
C5
C6a
C6b
C1'
C4'
α4
α6
βI
βII
γIV
γVI

Distance from spinlabel (Å) (± 3.5 Å)
9.8
11.9
10.6
12.1
14.6
10.4
10.3
9.4
9.2
19.7
11.5
9.6
9.9
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Figure 7.3: Spin-labeled lipid A schematic indicating atoms for which distances
were determined.
Atoms labeled in red correlate to the atom names listed with distances from the spin-label’s
unpaired electron, in Table 2.
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The calculated distances seem to agree with what would be expected for most of the lipid
A atoms, such as the distances for C1, C4, C5, C6a, βI, and βII. However, some of the
other resonances fall farther outside the anticipated distance ranges, estimated from our
NOE-derived unbound lipid A structure. These particular distances could be plausible
given the lack of a bound lipid A structure, using the calculated distances as restraints, as
well as the inherent uncertainty in using speculated distance range estimates as the
measure of feasibility. The residues whose calculated distances do not seem to fall
within the estimated distance ranges are C6a, γIV, γVI’, αIV, and αVI. The cause of
these discrepancies is unknown at this time. While a structure of lipid A using these
distances as restraints was not completed at the time of this writing, future generation of a
bound lipid A structure could provide a firmer estimate of these distances. The extensive
optimization and troubleshooting performed in this experiment has laid the foundation for
the collection of high quality spin-labeled ligand-CD14 NMR data in a future
investigation.
Application of spin-label derived distances to the production of a CD14 bound
lipid A structure could allow our lab to generate a model structure of the CD14-lipid A
complex. This is possible because CD14 does not undergo significant global
conformational changes upon ligand binding. This allows a lipid A structure in the bound
conformation to be docked into the homology model of truncated sCD14 to yield a model
of the complex. Creation of a CD14-lipid A complex from the experimentally derived
bound lipid A structure will give a considerably more accurate complex structure than
one produced using only molecular dynamics simulation.
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CHAPTER 8. CONCLUSIONS
The TLRs may be the first signaling step in the complex inflammatory signal
cascade found in the innate immune system, but CD14’s role in over-activating the
inflammatory response has made studying its differential endotoxin recognition vitally
important.
In the course of our investigations of CD14, we have demonstrated that the
pattern recognition hypothesis, which stated that CD14 uses pathogen-associated
molecular patterns to recognize endotoxin ligands, is well founded. This was revealed by
the mapping and comparison of chemical shift changes in the HSQC spectra of

15

N

labeled CD14 in the presence and absence of gram-negative and gram-positive endotoxin.
The observation of changes to a common set of resonances with each endotoxin as well
as distinct endotoxin specific changes proved that CD14’s versatile differential ligand
recognition abilities are based in the use of common as well as specific interactions to
bind endotoxins.
The potential to produce specific antagonists that function to mitigate the
inflammatory response upstream of the TLRs would be a tremendous benefit in the
treatment of sepsis. By competing against the excessive amounts of endotoxin present in
the host during sepsis, an antagonist acting on CD14 could slow the constant
inflammatory signal being generated, dampening the inflammatory response. For this
reason, a detailed NMR investigation of the structural features of Kdo 2 -Lipid A’s
interactions with CD14 was undertaken. The result of this work was the first direct
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observation and identification of the lipid A structural elements strongly affected by
CD14 binding. Identification of these features lays the groundwork for the future design
of an antagonist.
The complementary study of isotopically labeled LTA’s interactions with CD14
provided further insight into the nature of pattern recognition by CD14. This
demonstrated how the interaction of CD14 with similar/common structural features of
endotoxins, such as the acyl chains, could contribute to the broad recognition of
endotoxin ligands by CD14.
The ability of CD14 to bind a wide range of diverse ligands is an impressive but
perplexing attribute given CD14’s lone binding site. As a result of investigating CD14’s
recognition of LPS and LTA, and again while determining the structural features of lipid
A involved in interactions with CD14, dynamic changes in CD14 were continually
revealed. Through the modulation of temperature and pH, we were able to use NMR to
observe the broad scope of conformational states that some CD14 residues are able to
sample. The capacity of CD14 to use dynamics to modulate which residues it uses in an
interaction with a ligand clearly displays a level of structural versatility that is translated
into its aptitude for recognizing and interacting with numerous endotoxin ligands. Based
on this, we can hypothesize that ligands recognized by CD14 interact using a
combination of hydrophobically driven interactions between its hydrophobic pocket and
the acyl chains found on many endotoxin cell wall components, while also using groups
of charged residues in its hydrophilic rim to make specific interactions with the polar
sugar head groups common to many endotoxins. It is also plausible that ligands could
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interact with CD14 primarily through electrostatic interactions with the hydrophilic rim.
For example, dsRNA has many exposed phosphate groups, but has all its hydrophobic
features sequestered within the core of the helix.
Each of these investigations has provided new insights into the structure and
function of CD14, and has generated new data that could aid in the development of novel
anti-sepsis therapies. Potential therapies could make use of the structural features
identified as having strong interactions with CD14, such as the acyl chains, and
phosphate groups, as the basis for the directed design of a potential antagonist to use in
reducing the over-activated inflammatory response in cases of severe sepsis. A reduction
in the inflammatory response would provide more options and more time to treat a
patient’s underlying illness, without the devastating damage caused by the domino effect
of the inflammatory cascade. An example of this targeted design process is the synthetic
TLR4 antagonist eritoran. Eritoran is a synthetic LPS, whose structure was designed
based on the weakly antagonistic lipid A of Rhodobacter sphaeroides (189). Currently in
phase II trials, eritoran has been shown to block some of the effects of endotoxin in
humans, illistrating the value of structural data on the binding and recognition of
endotoxin by the innate immune system.
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A.1 1H and 13C NMR ASSIGNMENTS FOR Escherichia coli Kdo 2 -LIPID A

Table A1. 1H and 13C NMR assignments for E. coli Kdo 2 -Lipid A
Assignment (ppm)a
Resonance
C1-H1
C2-H2
C3-H3
C4-H4
C5-H5
C6-H6a/b
C1’-H1’
C2’-H2’
C3’-H3’
C4’-H4’
C5’-H5’
C6’-H6’
K1C2-K1H2a/b
K1C3- K1H3
K1C4- K1H4
K1C5- K1H5
K1C6- K1H6
K1C7- K1H7
K2C2-K2H2
K2C3- K2H3
K2C4- K2H4
K2C5- K2H5
K2C6- K2H6
K2C7- K2H7

1

H
5.22
3.89
4.99
3.42
3.92
3.81/3.60
4.34
3.63
4.89
3.73
3.3
3.68/3.50
1.53/1.88
3.72
3.53
3.56
3.68
3.49
1.71
3.89
3.9
3.57
3.47
3.30/3.58

13

C
95.31
53.22
75.24
68.76
72.65
69.4
103.08
55.16
74.59
73.94
74.5
64.88
36.39
72.68
65.52
71.48
67.47
64.96
35.09
69.41
65.52
72.65
75.89
63.58

Acyl chains
αΙ
αΙΙ
αΙΙΙ
αΙV

2.08
2.18
2.31
2.1

44.8
44.16
42.86
37.03
168

αV
αVI
βI
βΙΙ
βΙΙΙ
βΙV
βV
βVI
γΙ
γΙΙ
γΙΙΙ
γΙV
γV
γVI
(CH 2 )n
Ω(-CH 3 )
a1

2.48
2.09
3.67
3.72
4.94
1.31
4.97
1.37
1.19
1.26
1.32
1.06
1.4
1.18
1.01, 1.04, 1.05
0.65

40.92
35.09
70.7
71.35
72.65
26.67
71.33
25.38
38.33
38.98
35.74
26.67
36.39
27.32
24.08, 34.44, 30.56
15.02

H and 13C chemical shifts at 17 ºC in CDCl 3 :CD 3 OD:D 2 O (2:3:1, v/v) relative to DSS.
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A.2 WESTERN BLOT PROCEDURES FOR ANALYSIS OF Pichia pastoris
EXPRESSED SOLUBLE CD14
For western blot analysis pure sCD14 samples (~1 μg) were mixed with 2x SDS
sample buffer and boiled for 10 minutes. A 15-well Novex 18% tris–glycine gel
(Invitrogen, Carlsbad, CA) was then loaded in duplicate with 15 μl/well of boiled sCD14
sample, and 8 μl/well of pre-stained broad range protein molecular weight (Promega,
Madison, WI). The gel was then run in tris-glycine SDS running buffer at 125 V for 90
minutes at 4 ºC, using a SureLock Xcell mini-cell electrophoresis unit (Invitrogen). After
the separation, half the gel was stained in Coomassie-blue overnight, and de-stained the
following morning. The other half of the gel was transferred overnight onto a PVDF
membrane (Pierce, Rockford, IL) at 4 ºC using the Xcell II blotting module (Invitrogen)
with a constant current of 25 V. All buffers used in the separation and transfer steps were
prepared following the Invitrogen’s recommendations, the lone exception being the trisglycine transfer buffer was prepared containing only 10% methanol rather than the
standard 20%. The transfer of higher weight molecular proteins onto the PVDF
membrane was significantly improved by reducing the methanol content of the transfer
buffer.
Following the transfer the PVDF membrane was incubated in blocking buffer, 5%
powdered milk in TBST (10 mM Tris (pH 7.4), 150 mM NaCl, 0.1% Tween-20), for 1
hour at room temperature. The membrane was washed three times with 25 ml of TBST,
and then incubated for three hours in 8 ml of blocking buffer containing the monoclonal
CD14 antibody MEM-18 (Abcam, Cambridge, MA), diluted 1:1000. This was followed
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by two 15 minute, 25 ml TBST washes, next 8 ml of blocking buffer containing a 1:2000
dilution of the secondary antibody, anti-mouse IgG conjugated to horseradish peroxidase
(HRP) (Abcam). The membrane was incubated in the secondary antibody for 1 hour.
After three 25 ml washes in TBST the blot was either developed using the colorimetric
reagent metal-enhanced DAB (Pierce) or was developed in SuperSignal West Pico
chemiluminescent substrate (Pierce), and visualized by exposing the membrane to x-ray
film. Both development reagents were used per the manufacturer’s directions.
An alternative single antibody development procedure followed the same
development steps, but required no secondary antibody incubation, and skips straight to
the washing and visualization steps after the primary antibody incubation. This
abbreviated protocol used a monoclonal anti-6xHis tag antibody directly conjugated to
HRP (BD Bioscience, San Jose, CA). After the transfer and two TBSt wash steps, the
membrane was incubated for 1 hour in 8 ml of anti-6xHis tag antibody diluted 1:300 in
blocking buffer. Visualization of the blot was carried out as described above.
Alternatively, the PVDF membrane was developed using Millipore’s Snap i.d.
system. The Snap i.d. was used following the manufacturer’s directions, the membrane
was blocked using 30 ml of 0.5% powdered milk in TBST, and incubated for 10 minutes
in 3 ml of MEM-18, diluted 1:2500 in blocking buffer, followed by a 30ml wash with
TBST, and a 10 minute incubation with 3 ml of anti-mouse IgG conjugated to HRP,
diluted 1:5000. The anti-6xHis-HRP conjugated antibody was diluted 1:800 in 3 ml of
0.5% powdered milk blocking buffer. Final visualization of the blot was carried out as
described above using either the metal-enhanced DAB or the SuperSignal
171

chemiluminescent substrate.
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